

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
30 September 2004 (30.09.2004)

PCT

(10) International Publication Number
WO 2004/082719 A1

- (51) International Patent Classification?: **A61K 47/44**, 45/06
- (74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., P.O. Box 1027, St. Louis, MO 63006 (US).
- (21) International Application Number: PCT/IB2004/000802
- (22) International Filing Date: 10 March 2004 (10.03.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/456,201 20 March 2003 (20.03.2003) US
- (71) Applicant (for all designated States except US): **PHARMACIA CORPORATION** [US/US]; 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **BRITTEN, Nancy, J.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **BURNS, John, W.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **HALLBERG, John, W.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **WALDRON, Nikl, A.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US). **WATTS, Jeffrey, L.** [US/US]; Pfizer Global Research and Development, 700 Chesterfield Parkway West, Chesterfield, MO 63017-1732 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
- with international search report
 - before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: **DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS**

(57) Abstract: A method is provided for treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The method comprises administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy with the antibacterial agent a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent and, optionally, the second agent, are administered as a pharmaceutical composition further comprising a vehicle that comprises an amphiphatic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a pharmaceutically acceptable non-aqueous carrier. Also provided is such a composition comprising the antibacterial agent and the second agent. The composition is readily dispersible in the fluid of the fluid-containing organ.



WO 2004/082719 A1

DISPERSIBLE PHARMACEUTICAL COMPOSITION FOR TREATMENT OF MASTITIS AND OTIC DISORDERS

5

FIELD OF THE INVENTION

The present invention relates to a method of treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, such as the udder of a milk producing animal or an ear. The invention also relates to a dispersible pharmaceutical composition suitable for infusion into the organ according to the method of the invention, and to a process for preparing such a composition.

BACKGROUND OF THE INVENTION

Mastitis is an inflammation of the mammary gland of milk producing animals, for example dairy cows, most often caused by bacterial infection. Bacteria enter through the teat canal of the animal and can cause acute, clinical, or sub-clinical mastitis. Over 135 organisms have been documented as causative pathogens for bovine mastitis. Three of the major groups of pathogens are gram-positive cocci, gram-negative bacilli and gram-positive bacilli. Hygiene, environmental factors and metabolic disturbances deriving from high milk yield combine to create conditions favorable to the onset of mastitis. An increased somatic cell count, associated with mastitis, is positively correlated with infection and negatively correlated with milk production. Frequently, an infected cow must be removed from the herd and dried up. Mastitis often affects a cow during its entire life unless the disease is properly treated. Infection rates average from 10% to 30% of the cows in a typical herd, with losses per cow ranging from \$185 to \$250 per cow per year. Bovine mastitis is the most economically costly disease to the dairy industry, with losses estimated at two billion dollars annually in the United States alone. The majority of these losses are due to reduced milk production.

Intramammary administration of compositions comprising an antibiotic for treatment of mastitis in milk producing animals is well known. Several compositions suitable for such administration are formulated as oil based formulations.

U.S. Patent No. 3,636,194 to Parizeau discloses a composition for treating mastitis by intramammary infusion, comprising an antibiotic, a vegetable oil, an

alcohol-soluble fraction of natural lecithin phospholipid material for promoting dispersion of the oil in milk, the phospholipid being selected from the group consisting of phosphatidyl choline and phosphatidyl ethanolamine and mixtures thereof and present in an amount of at least 0.25% in said oil. Such compositions are said to provide rapid dispersion into milk and short milkout times.

British Patent Application No. 1,181,527 discloses a composition for treating mastitis comprising an active substance and a pharmaceutically acceptable oil base, said composition containing phospholipid material consisting substantially entirely of alcohol-soluble material for promoting dispersion of the composition in milk.

European Patent Application No. 0 222 712 discloses a composition which contains one or more antimicrobial agents dispersed in an oil consisting of a mixture of triglycerides of palmitic and stearic acid together with polyoxyethylenated cetyl alcohol and stearyl alcohol, and held in an oily medium of mineral, vegetable, synthetic or mixed extraction. Such compositions are said to speed up release of the antimicrobial agent in the udder, enhancing its biological potential, and reducing milkout time.

U.S. Patent No. 5,756,529 to Isakson & Talley discloses a method of using pyrazolyl benzenesulfonamide compounds to treat inflammation in a companion animal. Such compounds are said to be useful for treatment of pain, fever, joint disease, traumatic injury, arthritis, myositis, tendinitis, equine colic, mastitis, peritonitis, skin conditions, burns, gingivitis, hypersensitivity, conjunctivitis, eye inflammation, swelling and myocardial ischemia.

International Patent Publication No. WO 02/22107 discloses compositions comprising one or more bioactive agents in a liquid carrier, which has been modified to have an increased level of oxidation products, wherein the bioactive agents include anti-infectives, antineoplastics, immunomodulators, antipyretics, analgesics and anti-inflammatory agents (*e.g.*, cyclooxygenase-2 (COX-2) inhibitors). Such compositions can be administered by a parenteral (*e.g.*, subcutaneous, intramammary, intravenous, intraperitoneal or intramuscular), topical, intravaginal, oral, or rectal route.

International Patent Publication No. WO 02/06865 discloses a composition comprising one or more bioactive substances in a non-aqueous carrier wherein the composition has been adjusted to have a water activity of about 0.2 to about 0.5. Parenteral, topical, oral, intravaginal, rectal and intramammary routes of

administration are proposed. Among the bioactive agents listed are anti-infectives, antineoplastics, immunomodulators, antipyretics, analgesics and anti-inflammatory agents (*e.g.*, COX-2 inhibitors).

International Patent Publication No. WO 99/20259 discloses a combination of
5 thiamphenicol and diclofenac for use in veterinary medicine to treat infections with associated inflammatory conditions.

International Patent Publication No. WO 01/60409 discloses a paste composition comprising a therapeutic agent, fumed silica, a viscosity modifier and a hydrophilic carrier; wherein the therapeutic agent is selected from insecticides,
10 acaricides, parasiticides, antibiotics, growth enhancers, oil-soluble NSAIDs, avermectins, milbemycins, norduliporic acid, estrogens, progestins, phenylpyrazoles, substituted pyridyl methyl derivatives and COX-2 inhibitors. Oral, topical, dermal and subdermal routes of administration are contemplated for the paste composition. Such compositions are said to have application in veterinary practice in treatment of
15 diseases such as pneumonia, mastitis, metritis, rhinitis and bronchitis.

U.S. Patent Application Publication No. 2002/0032228 discloses use of a heterocycle containing compound, for example a diphenyl heterocycle derivative, to treat diarrheal diseases, whooping cough, anthrax, smooth muscle contraction conditions and mastitis. Celecoxib and rofecoxib are listed as preferred diphenyl
20 heterocycle derivatives.

A Labrafil product brochure (Notice OL 0050/5th edition) from Gattefossé Corporation contains an extract from a thesis by Valette (1957), discussing characteristics of Labrafil™ M-1944CS in the ear canal. The same thesis describes an experiment involving injecting Labrafil™ M-1944CS mixed with gentian violet into a
25 cow teat. It was shown that Labrafil™ wetted the entire surface of the mammary parenchyma section and reached the retromammary ganglion.

Two articles by Gao *et al.* (1995) in *Pharmaceutical Research* 12(6), 857-868, "Controlled release of a contraceptive steroid from biodegradable and injectable gel formulations: *in vitro* evaluation" and "Controlled release of a contraceptive steroid
30 from biodegradable and injectable gel formulations: *in vivo* evaluation", describe preparation of gels containing levonorgestrel, Labrafil™ M-1944CS and glyceryl palmitostearate.

Otic disorders rank second only to the common cold as the most frequent

illness among children in the United States. Most otic disorders are the result of a painful inflammatory response to infections, allergic reactions, or trauma to the ear. An otic infection may be of bacterial, fungal or viral origin and determination of the precise etiology is not practical since the causative organism is often difficult to
5 isolate and culture. Otitis externa (external ear infections), otitis media (middle ear infections) and otorrhea (otitis media with ruptured ear drum causing effusion) are among the most prevalent otic disorders.

Otitis externa, involving the ear canal portion of the external ear, is a common otological problem occurring mainly during hot, humid weather, and five times more
10 frequently in swimmers than in non-swimmers. In the incipient stage, symptoms include itching and pain in the ear canal, and tenderness when pressure is applied around the external auditory canal, the ear lobe is pulled or the jaw is moved. In the definitive stage, suppuration occurs in the ear canal and hearing may be decreased. Over 90% of cases of otitis externa are due to bacterial and fungal infections.

Pathological conditions can arise from, and can cause, changes in the surface tension of air/liquid interfaces of tissue surfaces, especially epithelial surface tissues. The external auditory canal is lined with epithelium. The cerumen exudate, normally secreted upon the epithelial tissue lining the external auditory canal, imparts a particularly high surface tension thereto. Inflammatory by-products can further
15 increase such surface tension. Increased surface tension is an important factor in both the symptoms and treatment of otitis. In addition, and even in the absence of canal closure, the increased surface tensions resident upon the epithelial lining of the outer ear canal, tends to inhibit uniform and/or effective application of therapeutic agents.

In the past, otitis externa has been treated with topical application of
25 therapeutic agents demonstrating antimicrobial activity as well as anti-inflammatory action. Broad spectrum topically effective antibiotic otic suspensions containing antibacterial agents, for example neomycin sulfate, colistin sulfate, polymyxin B, or combinations thereof, all broad spectrum in effect, have been utilized to destroy causative bacteria. Antimycotic topically acting agents, for example nystatin and
30 clotrimazole, have been employed to destroy underlying fungal disease. In addition, the antiviral agent acyclovir has been utilized to treat viral otitis externa including herpes zoster.

Anti-inflammatory agents including, for example, hydrocortisone,

hydrocortisone acetate and dexamethasone sodium phosphate, often included in the topically acting suspensions identified above, have been employed to control the inflammatory process of otitis externa. Most often, antimicrobial and anti-inflammatory agents are utilized in combination to treat the causative, triggering disorder, e.g., bacterial infection, as well as the inflammatory process itself. They are also most often administered as suspensions in drop form for topical administration to the affected ear. In order to enhance and provide a more uniform delivery of such medications to the epithelial lining of the outer ear canal, wicks, made of absorbent material such as cotton, are utilized to draw the suspension into the ear canal.

However, due to the exudate present in purulent forms of otitis externa, and the cerumen present in virtually all inflammatory conditions, high surface tension resists uniform distribution of such medications throughout the external auditory canal.

The most common otic disorder, otitis media, is a leading cause of hearing loss in the United States and represents a significant disability interfering with childhood learning processes. See Estrada (1997), *Infect. Med.* 14(3), 239-244. Otitis media accounts for over 35 percent of all childhood visits to pediatricians each year and represents more than \$3.5 billion in U.S. health care costs annually.

During episodes of otitis media, the relatively high surface tensions present at the air/liquid interface located upon the epithelial lining of the tube lumen increase the opening pressure required to open this channel.

Typically otic infective disorders such as otitis media are treated with a course of antibiotic therapy. See *The Merck Manual*, 17th edition (1999), Section 7, Chapter 84. Systemic administration of antibiotics generally requires high initial doses and an appreciable lag time to achieve therapeutic levels in the ear. Systemic application of drugs via parenteral or oral routes, while eventually reaching the eustachian tube and middle ear, may have adverse systemic effects and, more importantly, are not especially effective at delivering a concentrated dose of the applicable drugs where they are truly needed, directly to the target tissues. At the same time, direct drug application has been complicated by the sealed chamber anatomy of the middle ear.

Combinations of antibacterial and anti-inflammatory agents, formulated together in a pharmaceutically acceptable vehicle, have been proposed for topical application to the ear, in various patents and publications including those individually cited below.

U.S. Patent No. 6,395,746 to Cagle *et al.*

U.S. Patent No. 6,440,964 to Cagle *et al.*

U.S. Patent No. 6,509,327 to Cagle *et al.*

U.S. Patent No. 5,679,665 to Bergamini *et al.*

5 U.S. Patent No. 5,965,549 to Purwar & Goldman.

U.S. Patent Application Publication No. 2001/0049366.

U.S. Patent Application Publication No. 2002/0142999.

U.S. Patent Application Publication No. 2002/0044920 discloses treating
immune-mediated ear disorders by administering a TNF antagonist and a pyrimidine
10 synthesis inhibitor with a steroid, an anti-inflammatory compound (for example an
NSAID or a COX-2 inhibitor), a cytotoxic compound, an anti-neoplastic metabolite,
or a secondary antirheumatic agent.

U.S. Patent Application Publication No. 2002/0076383 discloses
administration of a composition as an aerosol through the external auditory canal, the
15 composition comprising a lipid surfactant in an amount effective in lowering surface
tension of an air/liquid interface upon epithelial tissue lining, a spreading agent and a
propellant, wherein the spreading agent is selected from the group consisting of lipids,
sterols, fatty acid, cholesterol esters, phospholipids, carbohydrates and proteins, all in
powder form. The composition is said to increase external auditory canal patency
20 while providing protection against occurrence of otitis externa.

U.S. Patent Application Publication No. 2002/0064503 discloses
administration of a composition as an aerosol through an external airway, wherein the
composition comprises a lipid surfactant in an amount effective in lowering surface
tension of an air/liquid interface upon epithelial tissue lining, and a spreading agent
25 selected from a group consisting of sterols, lipids, fatty acids, cholesterol esters,
phospholipids, carbohydrates and proteins, all in powder form. The composition is
said to increase the patency and pressure equalization performance of the eustachian
tube lumen.

Ear drops have been contemplated as a formulation type for selective COX-2
30 inhibitors, for example in the patents and publications individually cited below.

U.S. Patent No. 6,307,047 to Black *et al.*

U.S. Patent No. 6,329,526 to Adams *et al.*

U.S. Patent Application No. 2001/0041726.

U.S. Patent Application No. 2001/0053764.

U.S. Patent Application No. 2002/0010146.

U.S. Patent Application No. 2002/0013318.

All patents and publications cited above are incorporated herein by reference.

5 Despite recent advances that have been made in understanding the causes of otic disorders, they remain largely unpreventable and are difficult to effectively treat. It would be useful, therefore, to provide efficacious methods and compositions for the prevention and treatment of otic disorders and complications related thereto.

Very few antibacterial agents possess anti-inflammatory, antipyretic or
10 analgesic properties in addition to their antibacterial activity. Therefore, treating an infective condition with an antibacterial agent alone typically does not alleviate the inflammation, pain, swelling, fever and other complications that often accompany such an infective condition. These problems are usually not totally resolved until the causal organism of the infective condition has been eliminated or reduced to a
15 subpathogenic population by the antibacterial agent.

Treatment of an infective condition having an inflammatory component with an anti-inflammatory agent alone can reduce inflammation, swelling, pain, fever and other complications, but does not treat the underlying infective condition.

The most commonly used packaging containers and delivery devices for
20 compositions intended for intramammary administration to treat or prevent mastitis in milk producing animals as well as for compositions for otic administration to treat otic disorders are constructed of oxygen-permeable plastic materials, for example polyethylene, polypropylene, *etc.* and mixtures thereof. The use of oxygen-permeable packaging containers and delivery devices for anti-mastitis compositions and for
25 compositions for treatment or prevention of otic disorders poses serious problems for long term chemical and/or physical stability of a composition contained therein, if the composition comprises an ingredient, for example an active medicament or an excipient, that is prone to oxidative degradation.

Although the references cited above disclose a number of compositions for
30 treatment of mastitis or for treatment of otic disorders, none addresses the problem of providing extended chemical and/or physical stability of a composition packaged in an oxygen-permeable container, where the composition comprises a pharmaceutically active agent and/or excipient that is prone to oxidative degradation. Despite the above

5 teachings, there still exists a need in the art for pharmaceutical compositions having one or more of the following advantages over prior art compositions used in treatment of mastitis or otic disorders: (a) extended chemical and/or physical stability even when packaged in oxygen-permeable containers and delivery devices, particularly where the composition comprises a pharmaceutically active agent or excipient that is prone to oxidative degradation, (b) efficacy against a wide variety of infectious organisms, (c) effective treatment for the inflammatory component as well as the infectious component of mastitis or of an otic disorder, (d) effective treatment of the pain, inflammation, fever and infectious components of mastitis or otic disorders, (e) minimal to no irritation after administration of the composition, (f) targeted delivery of the active agent(s) to sites of infection, (g) rapid dispersibility of an anti-mastitis composition in milk and in udder fluids to quickly achieve efficacious medicament levels at sites of infection, (h) short milkout times following mastitis treatment for lactating cows, (i) zero day slaughter meat withdrawal period following mastitis treatment, (j) short milk withholding times post calving after dry cow mastitis treatment, (k) rapid dispersibility of an otic composition in the waxy moist environment of an ear to quickly achieve efficacious medicament levels at sites of infection, (l) a lowering of the surface tension of the air/liquid interface of epithelial tissue, increasing patency of the auditory canal, (m) a protective coating for inflamed mucous membranes of the ear, (n) improvement of the therapeutic index of an active agent while decreasing its general toxicity and minimizing the risk of systemic effects, (o) decreased time required to alleviate an infective condition having an inflammatory component, (p) reduction in side effects, (q) potential to administer a lower dose of an active agent while still providing efficacy, and (r) potential to administer a higher dose of an antibacterial agent without increased side effects.

SUMMARY OF THE INVENTION

Novel methods of treatment and pharmaceutical compositions having some or all of the advantageous attributes described above have now been developed. In particular, there is provided a novel method of treatment and/or prevention of an infective and/or an inflammatory condition in a fluid-containing organ having a natural exterior orifice, for example an udder of a milk-producing animal or an ear of a human or animal subject. The method comprises administering an antibacterial agent or an anti-inflammatory agent to the organ via the exterior orifice. The method

also comprises administering a combination therapy of the antibacterial agent and a second agent that is an anti-inflammatory agent, an analgesic and/or an antipyretic. The antibacterial agent is administered as a pharmaceutical composition comprising, in addition to the antibacterial and/or anti-inflammatory agents, a vehicle that
5 comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier.

Such a composition has low interfacial tension when placed in contact with an aqueous medium. It is believed, without being bound by theory, that this low interfacial tension results in the composition dispersing readily in udder fluids such as
10 milk as well as in the more waxy moist environment of an ear. In a preferred method of the invention, therefore, upon administration to the fluid-containing organ, the composition disperses in the fluid.

The method can, for example, comprise intramammary infusion of such a composition for treatment of mastitis or other diseases of the udder in a milk
15 producing animal, or otic infusion of such a composition for treatment and/or prevention of otic disorders, and is efficacious in a wide variety of infective disorders involving a wide variety of infectious organisms. The term "infusion" herein embraces any operation wherein a liquid composition is caused to flow into the fluid-containing organ via the exterior orifice, for example the teat canal in the case of
20 intramammary infusion or the external auditory canal in the case of otic infusion, regardless of the timescale involved. In the present context, "infusion" and "injection" are substantially synonymous. For example, the composition can be intramammarily administered by inserting the cannula nozzle of a mastitis syringe into the external orifice of a teat canal and injecting the composition through the nozzle
25 into the udder.

The second agent can be administered by a route that is other than the route of administration of the antibacterial agent. Alternatively, both agents can be administered by the same route, *i.e.*, via the exterior orifice of the organ, for example the teat canal in the case of an udder or the external auditory canal in the case of an
30 ear. Where administration is by the same route, it is preferred that the anti-inflammatory agent as well as the antibacterial agent be administered by intramammary or otic infusion in the form of a liquid composition comprising a vehicle as described above. It is especially preferred that the antibacterial agent and

the anti-inflammatory agent be administered in a single composition containing both agents.

Accordingly, there is further provided a pharmaceutical composition comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier. The vehicle has stably dispersed therein an antibacterial agent in an antibacterially effective amount and an anti-inflammatory agent, an analgesic and/or an antipyretic in a therapeutically effective amount.

In one embodiment the antibacterial agent, the anti-inflammatory agent and/or an excipient in the composition is prone to oxidative degradation, and the composition exhibits extended chemical and/or physical stability when packaged in a container or delivery device having an oxygen permeable wall.

The novel composition has a low interfacial tension in aqueous fluids, thereby increasing dispersibility of the composition in milk and udder fluids, as compared to a conventional oil based formulation. This results in rapid distribution of the composition throughout the udder and thereby allows the antibacterial agent and/or the second agent to reach infected tissue quickly, providing an efficacious level of medicament at a site of infection. The interfacial tension of a composition in an aqueous fluid determines the energy needed for dispersion and spreading of the composition in the fluid, as well as the energy necessary for a suspended particle in the composition to cross the oil/milk or oil/udder fluid interfacial boundary.

The low interfacial tension of the composition also increases dispersibility of the composition in the waxy moist environment of an ear, as compared to a conventional composition. The resulting rapid distribution of the composition throughout mucous membranes and lipid containing wax of the ear canal allows the antibacterial agent and/or the second agent to reach infected tissue quickly, providing an efficacious level of the medicament at the site of infection. Such a composition can also produce a protective coating for inflamed mucous membranes of the ear.

Combination therapy according to the invention provides effective treatment for both the infectious as well as the inflammatory components of an infective condition, and can reduce the time required to resolve the infective condition and associated inflammation. Preferably the method or composition provides effective treatment and/or prevention of the pain, inflammation, fever, swelling, redness, heat,

increased mucous or mucous/catarrhal secretions, anorexia, sensory dulling, loss of organ or system function, as well as the infectious components associated with mastitis or otic infections.

Inflammation associated with an infective condition can inhibit an
5 antibacterial agent from effectively reaching the site of infection. Use of a selective COX-2 inhibitor in combination therapy with an antibacterial agent reduces the inflammation associated with an infective condition and can result in improvement in the ability of the antibacterial agent to effectively reach the site of infection.

Certain antibacterial agents, while being very effective against infective
10 bacteria, are associated with a risk of undesirable side effects, such as transient redness, swelling and inflammation. Acceptable dosages of some antibacterial agents can be practically limited by the need to minimize risk of such side effects. The combination therapy method of the present invention minimizes these risks, thereby providing improved treatment of mastitis and otic conditions.

It is believed, without being bound by theory, that certain antibacterial agents,
15 when administered to certain subjects, can promote release of endotoxins that in turn sets off a TNF_α (tumor necrosis factor alpha) mediated response, and it is further believed that such response can be blocked or mitigated by the selective COX-2 inhibitor.

Combination therapy according to the invention can enable administration of a
20 lower dose of a therapeutic agent while still providing efficacy. Further, local administration of the antibacterial agent, and optionally the second agent, according to the invention provides targeted delivery to the site of infection and/or inflammation.

Combination therapy as provided herein can improve the therapeutic index of
25 an active agent by decreasing its general toxicity and minimizing the risk of systemic side events. Therapeutic index is a measure of the margin between a therapeutically effective dose and a toxic dose of a drug and is typically expressed as the ratio of LD_{50} (a dose lethal to 50% of a population) to ED_{50} (a dose therapeutically effective in 50% of the population).

When administered by intramammary infusion, for example in treatment of
30 mastitis, preferred methods and compositions can have additional advantages. For example, a preferred method enables suitably short milkout times. Milkout time for a lactating cow is the period of time from administration of a mastitis treatment to

resumption of production of saleable milk. Following such administration, the concentration of active agent(s) in milk must fall to a level acceptable to the appropriate regulatory body before the milk is deemed suitable for human consumption. A suitably short milkout time reduces monetary losses to a dairy farmer
5 caused by a mastitis outbreak.

Alternatively or in addition, a preferred method enables a low milk withholding time post calving after dry cow mastitis treatment, with no active agent residues in the offspring.

Alternatively or in addition, a preferred method enables a zero day slaughter
10 meat withdrawal period following mastitis treatment. This attribute is especially important since it allows a farmer to dispose of a treated cow at any time it is financially advantageous to do so, rather than being required to keep and feed a cow for a specified amount of time after its treatment.

The term "treatment" herein includes administration of a therapeutic agent to a
15 non-lactating animal, for example a dry cow, which does not yet show clinical signs of mastitis, but which is at risk for developing clinical mastitis. The invention therefore provides a method for reducing risk of developing clinical mastitis in a future lactating animal at such risk, the method comprising intramammary administration to the animal of an antibacterial agent in combination therapy with a second agent as defined
20 herein, in therapeutically effective amounts of each.

In a preferred embodiment, however, combination therapy according to the invention is administered to a milk producing animal that has clinical signs of mastitis. The invention therefore provides a method for treating clinical mastitis in a milk producing animal, the method comprising intramammary administration to the
25 animal, of an antibacterial agent in combination therapy with an anti-inflammatory agent as defined herein, in therapeutically effective amounts of each.

When administered by otic infusion, for example in treatment of infective disorders of the ear, preferred methods and compositions can have additional advantages. For example, a preferred method increases patency of the auditory canal
30 and thereby reduces resistance to conduction of sound, improving the clarity and sensitivity of hearing.

Alternatively or in addition, a preferred method provides a coating on the epithelial lining of the ear that protects against deleterious effects of water and water-

borne toxins, irritants and antigenic materials, and helps prevent otic disorders.

A further benefit of methods and compositions of the invention, whether for intramammary or otic use, is that they permit targeted delivery of at least the antibacterial agent to the site of infection and/or inflammation. Where a composition of the invention is used comprising both an antibacterial agent and a second agent as defined herein, targeted delivery of both agents is provided to the site of infection and/or inflammation.

A still further benefit of preferred compositions, whether for intramammary or otic administration, is that they cause minimal to no irritation after administration.

A still further benefit of a composition of the invention is improved physical stability when compared to conventional oil and aqueous compositions, for example by virtue of improved composition resuspendability. A composition of the invention has been shown to cause flocculation of certain drugs, thereby improving resuspendability and eliminating the problem of suspension caking and possible delivery of a subpotent or non-efficacious dose.

A process is provided for preparing a pharmaceutical composition of the invention. The process comprises mixing, in any suitable order, an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax, a pharmaceutically acceptable non-aqueous carrier, an antibacterial agent and a second agent as defined herein to provide the composition, such a composition preferably having extended chemical and/or physical stability as described herein.

The present invention thus provides solutions to several long standing problems in the art and possesses one or more advantages over methods and compositions of prior art. Other features, advantages and benefits of the invention will be apparent from the description that follows.

DETAILED DESCRIPTION OF THE INVENTION

The invention provides a method of treatment of an infective condition in a fluid-containing organ having a natural exterior orifice, the method comprising administering an antibacterial agent to the organ via the exterior orifice and administering in combination therapy therewith a second agent as defined herein; wherein the antibacterial agent is administered as a pharmaceutical composition comprising the antibacterial agent and a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a

pharmaceutically acceptable non-aqueous carrier.

It will be understood that reference herein to methods involving and compositions comprising “an antibacterial agent” embraces such methods and compositions wherein more than one antibacterial agent is used. Further, more than
5 one anti-inflammatory, antipyretic and/or analgesic agent can optionally form the “second agent” herein.

An “infective condition” herein includes any disease, disorder or condition mediated by a pathogenic bacterium or that is otherwise responsive to treatment with an antibacterial agent such as an antibiotic drug, whether or not accompanied by pain,
10 fever, swelling or inflammation. The invention is, however, especially drawn to such conditions having a component of pain, fever, swelling or inflammation.

A fluid-containing organ as contemplated herein includes a mammary organ, for example an udder of a milk producing animal such as a cow, a goat or a sheep. A “milk producing animal” can be a female of any mammalian species but is preferably
15 an animal raised for the purpose of providing milk, *e.g.*, a cow, a goat or a sheep, and encompasses such animals whether or not they are lactating at the time of the infective condition or at the time of treatment. The natural exterior orifice of the mammary organ is the orifice of the teat canal. A fluid-containing organ also includes an ear of a human or animal subject. The natural exterior orifice of the ear is the orifice of the
20 external auditory canal.

The term “antibacterially effective amount” as used herein refers to an amount of an antibacterial agent that is sufficient, when administered by the method of the invention, to reduce, relieve, prevent, or delay onset of one or more symptoms of an infective condition being treated, or to reduce numbers and/or activity of a causal
25 organism.

The term “combination therapy” herein means a treatment regimen wherein the antibacterial agent and the second agent are administered individually or together in such a way as to provide a beneficial effect from co-action of these therapeutic agents. Such beneficial effect can include, but is not limited to, pharmacokinetic or
30 pharmacodynamic co-action of the therapeutic agents. Combination therapy can, for example, enable administration of a lower dose of one or both agents than would normally be administered during monotherapy, thus decreasing risk or incidence of adverse effects associated with higher doses. Alternatively, combination therapy can

result in increased therapeutic effect at the normal dose of each agent in monotherapy. "Combination therapy" herein is not intended to encompass administration of two or more therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in sequential or simultaneous treatment.

5 Administration of the antibacterial agent and the second agent typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected). These therapeutic agents can be administered in a sequential manner, that is, at different times, typically separated by no more than about 24 hours, or in a substantially simultaneous manner.

10 When administered simultaneously, the antibacterial agent and the second agent can be administered in separate dosage forms or in coformulation, *i.e.*, in a single dosage form. When the two agents are administered sequentially or in separate dosage forms, the second agent can be administered by any suitable route and in any pharmaceutically acceptable dosage form, for example by a route and/or in a dosage
15 form other than that used for the antibacterial agent. Alternatively, the second agent, like the antibacterial agent, can be dispersed in a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier and administered via the natural exterior orifice of the fluid-containing organ. In a preferred embodiment,
20 both agents are co-dispersed in the same vehicle and administered in a single operation.

The term "therapeutically effective amount" as used herein refers to an amount of an active agent that is sufficient, when administered by the method of the invention, to reduce, relieve, prevent or delay onset of one or more symptoms of a condition
25 being treated, or to reduce numbers and/or activity of a causal organism. The phrase "in therapeutically effective amounts of each" means that when administered in combination therapy according to the method of the invention, the amount of the antibacterial agent and the amount of the second agent are sufficient to provide both an antibacterial effect and an effect selected from anti-inflammatory, analgesic and
30 antipyretic effects. Such amounts can be the same as, greater or less than the amount of antibacterial agent or the amount of the second agent that are therapeutically effective when used in monotherapy.

The "second agent" herein is an active pharmaceutical agent having analgesic,

antipyretic and/or anti-inflammatory properties. Preferably such an agent exhibits at least an anti-inflammatory effect when administered according to the invention.

The pharmaceutical composition comprising the antibacterial agent and, in certain embodiments, the second agent is a liquid injectable or infusible composition, for example a composition adapted for intramammary or otic infusion, having the agent(s) dispersed in a vehicle as described herein. The term "dispersed" in the present context means dissolved (*i.e.*, molecularly dispersed) or colloiddally dispersed, for example as an emulsion or suspension. Typically at least one of the therapeutic agents is suspended in solid particulate form in the vehicle.

The vehicle comprises three essential ingredients, optionally together with additional ingredients.

The first of these essential ingredients is an amphipathic oil that is water dispersible and ethanol insoluble. An "amphipathic oil" is defined as a substance having a molecular structure with a distinctly polar region and a distinctly non-polar region. Structurally these two regions of the amphipathic oil are sufficiently far apart that the unique properties of the two regions are distinctly separate. The term "ethanol insoluble" means that the amphipathic oil is essentially insoluble in ethanol at 20°C.

The second essential ingredient of the vehicle is microcrystalline wax.

The third essential ingredient of the vehicle is a pharmaceutically acceptable non-aqueous carrier. Such a carrier is typically an oil, as described more fully hereinbelow.

The selection of vehicle components is important in providing a composition that, upon administration to the fluid-containing organ, disperses in the fluid. It is believed, without being bound by theory, that such dispersion in the fluid within the organ results in targeted delivery of the antibacterial agent and, optionally, the second agent, to the site of infection in the organ.

Where the method of the invention comprises injection or infusion of the composition into an udder via the teat canal, a process described herein as "intramammary infusion" regardless of the timescale involved, it can provide effective treatment of mastitis, other diseases of the udder, and/or a condition associated with a mammary disease.

Where the method of the invention comprises injection or infusion of the composition into an ear via the external auditory canal, a process described herein as

“otic infusion” regardless of the timescale involved, it can provide effective treatment and/or prevention of an otic disorder and/or a complication associated therewith. The subject suffering such otic disorder or complication associated therewith can be a human, companion animal, horse, livestock or the like.

- 5 Examples of such otic disorders include, but are not limited to, otitis externa (external ear infections), otitis media (middle ear infections), including acute, secretory, serous and chronic forms of otitis media, otorrhea (otitis media with ruptured ear drum causing effusion), acute mastoiditis, infections related to otic surgical procedures (such as tympanostomy and the like), otosclerosis, otalgia, otic
- 10 pain, otic inflammation, otic bleeding, Lermoyez’s syndrome, Meniere’s disease, vestibular neuronitis, benign paroxysmal positional vertigo, herpes zoster oticus, Ramsay Hunt’s syndrome, viral neuronitis, ganglionitis, geniculate herpes, labyrinthitis, including purulent labyrinthitis and viral endolymphatic labyrinthitis, perilymph fistulas, presbycusis, drug-induced ototoxicity, acoustic neuromas, aerotitis
- 15 media, infectious myringitis, bullous myringitis, otic neoplasm, squamous cell carcinoma, basal cell carcinoma, other otic cancers, pre-cancerous otic conditions, nonchromaffin paragangliomas, chemodectomas, glomus jugulare tumors, glomus tympanicum tumors, perichondritis, aural eczematoid dermatitis, malignant external otitis, subperichondrial hematoma, ceruminomas, impacted cerumen, sebaceous cysts,
- 20 osteomas, keloids, tinnitus, vertigo, tympanic membrane infection, tympanitis, otic furuncles, petrositis, conductive and sensorineural hearing loss, epidural abscess, lateral sinus thrombosis, subdural empyema, otitic hydrocephalus, Dandy’s syndrome, bullous myringitis, diffuse external otitis, foreign bodies, keratosis obturans, otomycosis, trauma, acute barotitis media, acute eustachian tube obstruction, a
- 25 complication associated with any of the above infections (such as hearing loss, brain abscess, fever, cholesteatomas, calcification of the middle and inner ear, ruptured ear drum, meningitis, facial paralysis and the like), postsurgical otalgia and the like.

30 The method of the invention is particularly suitable for treatment of otitis externa, otitis media, otorrhea, and infections having an inflammatory component that are related to an otic surgical procedure.

 In one embodiment the otic disorder is a neoplasia. Examples of such neoplasia include, but are not limited to, otic neoplasia, squamous cell carcinoma, basal cell carcinoma, malignant external otitis, malignant nonchromaffin

paraganglioma, malignant jugulare tumor, malignant glomus tympanicum tumor, a pre-cancerous otic condition and the like.

Combination therapy of the antibacterial agent together with the second agent provides enhanced treatment options as compared to administration of either the antibacterial agent or the second agent alone. As indicated above, the antibacterial agent is dispersed in a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier, and is administered for example by intramammary or otic infusion, while the second agent is formulated into any acceptable immediate release or sustained release pharmaceutical dosage form. Suitable dosage forms for the second agent include, but are not limited to, a suspension, solution, emulsion, tablet, capsule, pill, powder, granules, elixir, tincture, syrup, lozenge, dragee, gel, ointment, spreadable paste, slurry, aerosol spray, ear drops, nasal drops, eye drops, suppository, implant and the like, and can be administered via any route including, but not limited to, oral, including peroral and intraoral, *e.g.*, sublingual, buccal, *etc.*; parenteral, *e.g.*, intramuscular, subcutaneous, intravenous, intraperitoneal, intra-articular, intradermal, intraspinal, intrasternal, intramedullary, intrasynovial, intrathecal, intracardiac, intraventricular, intracapsular, intracranial, *etc.*; intramammary, topical, transdermal, intranasal, otic, mucosal, rectal, intravaginal, pulmonary and the like.

Preferably the second agent is formulated in a pharmaceutically acceptable vehicle, and both the antibacterial agent and the second agent are administered into the same fluid-containing organ, for example by intramammary or otic infusion. A pharmaceutically acceptable carrier or vehicle is one that has no unacceptably injurious or toxic effect on the animal when administered as a component of a composition in an amount required herein. No excipient ingredient of such a carrier or vehicle reacts in a deleterious manner with another excipient or with the therapeutic agent(s) in a composition.

Optionally, administration of the therapeutic agents described above can take place in further combination with other biologically active agents and non-drug therapies. For example, for treatment of a cancerous or pre-cancerous otic condition (such as otic neoplasia, squamous cell carcinoma, basal cell carcinoma, malignant external otitis, malignant nonchromaffin paraganglioma, malignant jugulare tumor,

malignant glomus tympanicum tumor, a pre-cancerous otic condition and the like) an antineoplastic agent can be added to a combination therapy of the invention. Such antineoplastic agents include, but are not limited to, anastrozole, calcium carbonate, capecitabine, carboplatin, cisplatin, docetaxel, eflornithine, etoposide, exemestane, 5 fluoxymestrine, gemcitabine, goserelin, irinotecan, ketoconazole, letrozol, leucovorin, levamisole, megsetrol, paclitaxel, raloxifene, retinoic acid, selenium (selenomethionine), sulindac sulfone, tamoxifen, thiotepa, topotecan, toremifen, vinbastine, vincristin, vinorelbine and the like, and combinations thereof.

In all embodiments of the invention, at least the antibacterial agent is 10 administered locally. An essential requirement for successful therapy of a local infective condition such as mastitis is that an antibacterial agent must reach the site of infection at a concentration near or higher than the minimal inhibitory concentration and that such concentration must be maintained for a certain minimal time. There are significant differences among antibacterial agents in their ability to reach a site of 15 infection in, for example, an udder, and these are greater than the differences in their intrinsic antibacterial activities. One advantage of local administration according to the invention is that the antibacterial agent and, preferably, the second agent, are preferentially directed toward their site of action, resulting in more rapid onset of therapeutic action and more complete delivery to the site of infection, compared with 20 other routes of administration such as intramuscular, subcutaneous and oral routes. Local administration can allow the total therapeutic dose for a given effect to be decreased and avoids the hepatic first pass effect. In addition, local administration decreases or eliminates secondary effects, especially those linked to one or both of the active agents, at sites other than the site of infection. Local administration of an active 25 agent can also improve its therapeutic index by decreasing its general toxicity and minimizing risk of undesirable systemic effects.

The invention provides, in a further embodiment, a pharmaceutical composition adapted for intramammary infusion, comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) 30 microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier; the vehicle having stably dispersed therein an antibacterial agent in an antibacterially effective amount and a second agent as defined herein in a therapeutically effective amount. Such a composition is suitable for single administration providing

combination therapy in accordance with the method of the invention.

Preferably such a composition lowers the high surface tension of the air/liquid interface of epithelial tissues associated with an otic disorder, so as to increase patency of the auditory canal. A decrease in the surface tension of the air/liquid interface of the epithelium lining can minimize fluid accumulation, and in some instances enable evacuation of fluids held in the canal due to elevated surface tensions therein, and/or allow separation of the proximal and opposing epithelial walls of the auditory canal (often brought closer together due to elevated surface tension of the tissues) thereby improving conduction of sound. The term "increase patency" as used herein refers to opening, and reduction or elimination of blockage, of the auditory canal so as to form a patent conduit. Resistance to conduction of sound results from reduction of the volume, partial obstruction, or complete occlusion of the auditory canal due to swelling of the epithelial walls as a result of inflammation, the accumulation of increased amounts of cerumen secreted thereupon, and/or collection of fluids therewithin, including fluids containing waste products of the immune response or exogenous water.

In a particular embodiment of the invention an ingredient of the composition (the antibacterial agent and/or the second agent and/or an excipient ingredient) is prone to oxidative degradation. Such a composition exhibits extended chemical and/or physical stability even when packaged in an oxygen permeable container or delivery device. The term "extended chemical and/or physical stability" herein means that a composition of the present embodiment has greater chemical and/or physical stability than a reference composition comprising the same medicament at the same concentration. A "reference composition" in the present context means a composition lacking one or both of the amphipathic oil and the microcrystalline wax, but otherwise similar to the composition of the invention.

Oxygen permeable containers or delivery devices can be made of any suitable thermoplastic material. Examples of such materials include, but are not limited to, polymers and copolymers of polystyrene, polyacrylonitrile, polyvinyl chloride, and particularly polyolefins. Polyolefins include, for example, polyethylene, polypropylene, polybutenes, polyisoprenes, polypentenenes, copolymers thereof and mixtures thereof.

Compositions for intramammary administration are commonly packaged in

syringes that are provided with a cannula nozzle for insertion into the teat to allow extrusion of the composition directly into the mammary gland via the teat canal. Intramammary suspension formulations are generally prepared in thickened vehicles to prevent settling of drug particles in the cannula nozzle, which can cause nozzle plugging resulting in incomplete expulsion of the composition.

Cephalosporins are a class of antibacterial substances, many of which have a broad spectrum of activity against both gram positive and gram negative bacteria.

In an early effort by the present applicant to develop an intramammary suspension of the cephalosporin ceftiofur, 12.5 mg/ml ceftiofur hydrochloride was suspended in a thickened vehicle comprising 20 mg/ml glyceryl monostearate in peanut oil. Although clinically efficacious, the potency of this composition fell to below 90% of label after storage for less than 18 months at room temperature when packaged in polyethylene syringes. Oxidative degradation of ceftiofur hydrochloride was determined to be the primary cause of this potency decline. A room temperature shelf life wherein at least 90% of label potency is retained for a minimum of 24 months is desired for an intramammary suspension.

A number of ceftiofur hydrochloride suspension compositions were then prepared in a variety of thickened vehicles and packaged in oxygen permeable polyethylene syringes. Ceftiofur hydrochloride formulations at a concentration of 12.5 mg/ml were manufactured. All vehicles were based on cottonseed oil, with the following additional components:

- 1) 50 mg/ml microcrystalline wax.
- 2) 70 mg/ml microcrystalline wax + 1.0 mg/ml propyl gallate.
- 3) 100 mg/ml microcrystalline wax + 50 mg/ml Labrafil™ M-1944CS.
- 4) 40 mg/ml Gelucire™ 62/05 + 10 mg/ml Gelucire™ 33/01.
- 5) 70 mg/ml Lexemul™ AR.
- 6) 2.5 mg/ml Coagulan™ GP-1.
- 7) 10 mg/ml microcrystalline wax + 5 mg/ml Hydrofol Glycerides™ T 57L.
- 8) 30 mg/ml Drewpol™ 10-10-S.
- 9) 15 mg/ml beeswax blend.
- 10) 60 mg/ml Drewpol™ 10-10-S.
- 11) 10 mg/ml beeswax blend + 50 mg/ml Labrafil™ M-1944CS.
- 12) 100 mg/ml microcrystalline wax + 1.0 mg/ml propyl gallate.

- 13) 70 mg/ml microcrystalline wax + 100 mg/ml Labrafil™ M-1944CS.
14) 70 mg/ml microcrystalline wax + 100 mg/ml Labrafil™ M-1944CS +
0.2 mg/ml butylated hydroxytoluene.
15) 70 mg/ml microcrystalline wax + 50 mg/ml Labrafil™ M-1944CS +
5 1.0 mg/ml propyl gallate.
16) 70 mg/ml microcrystalline wax + 50 mg/ml Labrafil™ M-1944CS +
0.2 mg/ml butylated hydroxytoluene.
17) 50 mg/ml microcrystalline wax + 1.0 mg/ml propyl gallate.
18) 100 mg/ml microcrystalline wax + 100 mg/ml Labrafil™ M-1944CS + 1.0
10 mg/ml propyl gallate.
19) 100 mg/ml microcrystalline wax + 100 mg/ml Labrafil™ M-1944CS + 0.2
mg/ml butylated hydroxytoluene.
20) 100 mg/ml microcrystalline wax + 50 mg/ml Labrafil™ M-1944CS +
1.0 mg/ml propyl gallate.
15 21) 100 mg/ml microcrystalline wax + 50 mg/ml Labrafil™ M-1944CS +
0.2 mg/ml butylated hydroxytoluene.
22) 50 mg/ml microcrystalline wax + 100 mg/ml Labrafil™ M-1944CS +
0.2 mg/ml butylated hydroxytoluene.

Labrafil™ M-1944CS is an amphipathic oil that is dispersible in water and is
20 essentially insoluble in ethanol at 20°C. Gelucire™ 62/05 and Gelucire™ 33/01 are
essentially inert excipients derived from natural hydrogenated food grade fats and oils.
Lexemul™ AR is an acid stable cationic, self emulsifying glyceryl monostearate.
“Beeswax blend” refers to a blend containing white beeswax, carnauba wax and
candelilla wax. Coagulan™ GP-1 is N-acyl glutamic acid diamide, an amino acid
25 gelatinization agent for oil. Drewpol™ is a modified glyceride.

Most surprisingly, it was discovered that after 24 months storage at room
temperature in oxygen permeable polyethylene syringes, only those ceftiofur
hydrochloride compositions comprising both Labrafil™ M-1944CS and
microcrystalline wax provided formulations that maintained at least 90% of label
30 potency. Estimated room temperature shelf lives for the ceftiofur hydrochloride
formulations comprising both Labrafil™ M-1944CS and microcrystalline wax in
cottonseed oil were 2.4 to 3.7 times greater than estimated room temperature shelf
lives of comparable formulations which did not contain Labrafil™ M-1944CS.

Additionally, while a ceftiofur hydrochloride composition comprising Labrafil™ M-1944CS and beeswax blend in cottonseed oil, stored at room temperature, had a potency of less than 90% after storage for 24 months in oxygen permeable polyethylene syringes at room temperature, a ceftiofur hydrochloride formulation of comparable viscosity comprising Labrafil™ M-1944CS and microcrystalline wax in cottonseed oil exhibited a potency of greater than 90% of label after 24 months in the same storage conditions.

Compositions comprising a cephalosporin, an amphipathic oil that is water dispersible and ethanol insoluble, microcrystalline wax and a non-aqueous carrier, in addition to providing extended chemical and/or physical stability, can also provide efficacy against a wide variety of infectious organisms, rapid dispersion of the composition in milk and in udder fluids to quickly achieve efficacious medicament levels at the site of infection, short milkout times for lactating cows, a zero day slaughter meat withdrawal period, short milk withholding times post calving after dry cow treatment, and minimal to no irritation after administration.

Antibacterial agents applicable for use according to the invention include any such agents that are effective for treatment and/or prevention of mammary disorders and/or otic disorders and/or complications associated therewith. Suitable antibacterial agents include, but are not limited to, beta-lactam antibacterials such as natural and synthetic penicillin type agents including penam penicillins (such as benzyl penicillin, phenoxymethyl penicillin, coxacillin, nafcillin, methicillin, oxacillin, amoxycillin, temocillin, ticarcillin and the like), penicillinase-stable penicillins, acylamino and carboxypenicillins (such as piperacillin, azlocillin, mezlocillin, carbenicillin, temocillin, ticarcillin and the like), and broader spectrum penicillins (such as streptomycin, neomycin, framycetin, gentamicin, apramycin, amikacin, spectinomycin, amoxycillin, ampicillin and the like), cephalosporins, macrolides (such as tylosin, tilmicosin, aivlosin, erythromycin, azithromycin, spiramycin, josamycin, kitasamycin and the like), lincosamides (such as lincomycin, clindamycin, pirlimycin and the like), pleuromutilins (such as tiamulin, valnemulin and the like), polypeptides, glycopeptides (such as vancomycin and the like), polymyxins (such as polymixin B, polymixin E and the like), sulfonamides (such as sulfamethazine, sulfadiazine, silver sulfadiazine, sulfatrazole, sulfamethoxy pyridazine, sulfanilamide, sulfamethoxazole, sulfisoxazole, sulfamethizole, mafenide and the like,

- alone or in combination with trimethoprim), chloramphenicol, thiamphenicol, florfenicol, tetracycline type agents (such as tetracycline, chlortetracycline, oxytetracycline, doxycycline, minocycline and the like), quinolones and fluoroquinolones (such as ciprofloxacin, enoxacin, grepafloxacin, levofloxacin, lomefloxacin, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, cinocacin, nalidixic acid and the like), tiamulin, colistin, meropenem, sulbactam, tazobactam, methacycline, pyrimethamine, sulfacetamide, oxazolidinones, *e.g.*, eperezolid, linezolid, N-((5S)-3-(3-fluoro-4-(4-(2-fluoroethyl)-3-oxy-1-piperazinyl)phenyl)-2-oxy-5-oxazolidinyl)methyl)acetamide, (S)-N-((3-(5-(3-pyridyl)thiophen-2-yl)-2-oxy-5-oxazolidinyl)methyl)acetamide, 2,2-difluoro-N-(((5S)-3-[3-fluoro-4-(4-glycolylpiperazin-1-yl)phenyl]-2-oxo-1,3-oxazolidin-5-yl)methyl)ethanethioamide, (S)-N-((3-(5-(4-pyridyl)pyrid-2-yl)-2-oxy-5-oxazolidinyl)methyl)acetamide hydrochloride and the like, aminoglycosides (kanamycin, tobramycin, netilmicin and the like), aminocyclitols, amphenicol, ansamycin, carbaphenem, cephamycin, rifampicin, monobactam, oxacephem, streptogramins (such as quinupristin, dalbapristin and the like), cycloserines, mupirocin, urea hydroxamates, folic acid analogs (such as trimethoprim and the like), antibiotic-type antineoplastic agents (such as aclarubicin, actinomycin D, actinoplanone, aeropylsinin derivative, Nippon Soda anisomycins, anthracycline, azino-mycin-A, busucaberin, bleomycin sulfate, bryostatatin-1, calicheamicin, chromoximycin, dactinomycin, daunorubicin, ditrisarubicin B, doxorubicin, doxorubicin-fibrinogen, elsamicin-A, epirubicin, erbstatin, esorubicin, esperamicin-A1b, fostriecin, glidobactin, gregatin-A, grincamycin, herbimycin, idarubicin, illudins, kazuamycin, kesarirhodins, menogaril, mitomycin, mitoxantrone, mutamycin, mycophenolate mofetil, neoactin, oxalysine, oxanumycin, peplomycin, pilatin, pirarubicin, porothramycin, pyrimidamycin A, rapamycin, rhizoxin, rodorubicin, sibanomicin, siwenmycin, sorangicin-A, sparsomycin, steffimycin B, talisomycin, terpenectin, thiazine, tricozarin A, zorubicin, systemic antibacterials (such as 2,4-diaminopyrimidine), nitrofurans, marbofloxacin and the like, and combinations thereof.

- 30 It should be understood that any reference herein to a particular drug compound includes tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs of that compound and is not specific to any one solid state form of the drug unless the context so requires.

Preferred antibacterial agents are cephalosporins including, but not limited to, ceftiofur hydrochloride, ceftiofur free acid, *e.g.*, ceftiofur crystalline free acid, ceftiofur sodium, other ceftiofur salts, cephalexin, cephradine, cefquinome, cephacetrile, cefovecin, cefpodoxime, cephalonium, cephalonium, cefuroxime, cefazidime, cefoperazone, sodium cephemethcarboxylate, cephem heptahydrate, cephalosporin di- or tri-hydrate, cephradroxil monohydrate, cephalozin sodium monohydrate, cefiximine, cefixime, ceftizoxime, ceftriaxone, o-formylcefamandole, salts of 3-acetoxymethyl-7-(iminocetamido)-cephalosporanic acid derivatives, monohydrate of 7-(D- α -amino- α -(p-hydroxyphenyl)acetamino)-3-methyl-3-
 10 cephem-1-carboxylic acid, hydrochloride salt of syn-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-3-cephem-4-carboxylic acid, cephem acid addition salts, (pivaloyloxy)methyl 7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylate, cephalexin, cephalexin monohydrate, 7-(D-2-naphthylglycylamino)-3-methyl-3-cephem-4-carboxylic acid tetrahydrate and the like.
 15 The most preferred cephalosporins for use according to the present invention are ceftiofur and pharmaceutically acceptable salts thereof. Especially preferred are ceftiofur free acid, most especially in crystalline form, and ceftiofur hydrochloride.

Where the antibacterial substance is ceftiofur or a salt thereof, a preferred
 20 concentration range in a composition of the invention is about 1 to about 1000 mg/ml, more preferably about 5 to about 750 mg/ml, and still more preferably about 10 to about 100 mg/ml. For antibacterial substances other than ceftiofur, suitable concentration ranges that are antibacterially equivalent can be determined by one of skill in the art based upon published data.

The second agent can have one or more of anti-inflammatory, analgesic and antipyretic properties. Examples include, but are not limited to, aceclofenac, acetaminophen, *e*-acetamidocaproic acid, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid (aspirin), *S*-adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum
 30 bis(acetylsalicylate), amcinonide, amfenac, aminochlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylon, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen,

benzitramide, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, betamethasone, bezitramide, α -bisabolol, bromfenac, *p*-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, bucetin, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butophanol, 5 carbamazepine, carbiphene, carprofen, carsalam, celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline magnesium trisalicylate, choline salicylate, cinchophen, cinmetacin, cinnoxiam, ciramadol, clidanac, clobetasol, clocortolone, clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol, 10 crotpropamide, crotethamide, cyclazocine, deflazacort, dehydritestosterone, deracoxib, desomorphine, desonide, desoximetasone, dexamethasone, dexoadol, dextromoramide, dextropropoxyphene, dezocine, diamorphine, diampromide, diclofenac, difenamizole, difenpiramide, diflorasone, diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol acetate, dihydrocodeine phosphate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol, 15 dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, diphenhydramine hydrochloride, dipipanone, diprocetyl, dipyrone, ditazol, *dl*-chlorpheniramine maleate, droxicam, emorfazone, enfenamic acid, enoxolone, eprizole, eptazocine, etersalate, etheizamide, ethoheptazine, etodolac, ethoxazene, ethopheptazine, 20 ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene, etoricoxib, eugenol, felbinac, fenbufen, fenchlofenac, fenclozic acid, fendosal, fenoprofen, fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, fluclozide, flufenamic acid, flumethasone, flunisolide, flunixin, flunoxaprofen, fluocinolone acetonide, fluocinolone, fluocinolone acetonide, fluocortin butyl, 25 fluocortolone, fluoresone, fluorometholone, fluperolone, flupirtine, fluprednidene, fluprednisolone, fluprofen, fluproquazone, flurandrenolide, flurandrenolone acetonide, flurbiprofen, fluticasone, formocortol, fosfosal, furofenac, gentisic acid, glafenine, glucametacin, glycol salicylate, guaiazulene, halcinonide, halobetasol, halometasone, haloprednone, heroin, hydrocodone, hydrocortamate, hydrocortisone, hydromorphone, 30 hydroxypethidine, ibufenac, ibuprofen, ibuproxam, imidazole salicylate, indomethacin, indoprofen, isofezolac, isoflupredone acetate, isoladol, isomethadone, isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac, *p*-lactophenetide, lefetamine, levallorphan, levorphanol, levophenacyl-morphan, lofantil, lonazolac,

lornoxicam, loxoprofen, lysine acetylsalicylate, lysozyme chloride, mazipredone, meclofenamic acid, medrysone, mefenamic acid, meloxicam, meperidine, meprednisone, meptazinol, mesalamine, metazocine, methadone, methotrimeprazine, methylephedrine hydrochloride, methylprednisolone, methylsalicylate, metiazinic acid, metofoline, metopon, miroprofen, mofebutazone, mofezolac, mometasone, morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, nalorphine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenzazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpiperanone, noscapine, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxipinac, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalimide, pentazocine, perisoxal, phenacetin, phenadoxone, phenomorphan, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenyl acetylsalicylate, phenylbutazone, phenylpropanolamine hydrochloride, phenyl salicylate, phenylamidol, pikeprofen, piminodine, pipebuzone, piperylone, pirofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, pirofen, piroxicam, proglumetacin, proheptazine, promedol, propacetamol, properidine, propiram, propoxyphene, propyphenazone, proquazone, protizinc acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide *o*-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, serratiopeptidase, simetride, sudoxicam, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaprofenic acid, tiaramide, tilidine, tinoridine, tiopinac, tioprofen, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, tropesin, valdecoxib, viminol, xenbucin, ximoprofen, zaltoprofen, zidometacin, zomepirac and the like, and combinations thereof.


In one embodiment the anti-inflammatory agent is a steroidal anti-inflammatory agent. Suitable steroids include, but are not limited to, alclometasone, amcinonide, betamethasone, betamethasone 17-valerate, clobetasol, clobetasol propionate, clocortolone, cortisone, dehydrotestosterone, deoxycorticosterone, desonide, desoximetasone, dexamethasone, dexamethasone 21-isonicotinate,

diflorasone, fluocinonide, fluocinolone, fluorometholone, flurandrenolide, fluticasone, halcinonide, halobetasol, hydrocortisone, hydrocortisone acetate, hydrocortisone cypionate, hydrocortisone hemisuccinate, hydrocortisone 21-lysinate, hydrocortisone sodium succinate, isoflupredone, isoflupredone acetate, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisolone suleptnate, mometasone, prednicarbate, prednisolone, prednisolone acetate, prednisolone hemisuccinate, prednisolone sodium phosphate, prednisolone sodium succinate, prednisolone valerate-acetate, prednisone, triamcinolone, triamcinolone acetonide and the like, and combinations thereof.

In another embodiment the second agent is an analgesic, selected for example from alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, cyclazocine, desomorphine, dextromoramide, dextropropoxyphene, dezocine, diampromide, diamorphine, dihydrocodeine, dihydromorphine, dimenoxadol, dimpheptanol, dimethylthiambutene, dioxaphetylbutyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone, hydroxypethidine, isomethadone, ketobemidone, levallorphan, levorphanol, levophenacyl-morphan, lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine, myrophine, nalbuphine, nalorphine, narceine, nicomorphine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, papaveretum, pentazocine, phenadoxone, phenazocine, phenomorphan, phenoperidine, piminodine, piritramide, proheptazine, promedol, properridine, propiram, propoxyphene, sufentanil, tilidine, tramadol and the like, and combinations thereof.

In yet another embodiment the second agent is an NSAID, selected for example from salicylic acid derivatives (such as salicylic acid, acetylsalicylic acid, methyl salicylate, diflunisal, olsalazine, salsalate, sulfasalazine and the like), indole and indene acetic acids (such as indomethacin, etodolac, sulindac and the like), fenamates (such as etofenamic, meclofenamic, mefenamic, flufenamic, niflumic and tolfenamic acids and the like), heteroaryl acetic acids (such as acetaminophen, alclufenac, clidac, diclofenac, fenchlofenac, fentiazac, furofenac, ibufenac, isoxepac, ketorolac, oxipinac, tiopinac, tolmetin, zidometacin, zomepirac and the like), aryl acetic acid and propionic acid derivatives (such as alminoprofen, benoxaprofen, bucloxic acid,

- carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, naproxen sodium, oxaprozin, piroprofen, pranoprofen, suprofen, tiaprofenic acid, tioxaprofen and the like), enolic acids (such as the oxicam derivatives ampiroxicam, cinnoxicam, droxicam, lornoxicam, meloxicam, piroxicam, sudoxicam and tenoxicam, and the pyrazolone derivatives aminopyrine, antipyrine, apazone, dipyrone, oxyphenbutazone, phenylbutazone and the like), para-aminophenol derivatives (such as acetaminophen and the like), alkanones (such as nabumetone and the like), nimesulide, proquazone and the like, and combinations thereof.
- 10 In a preferred embodiment the anti-inflammatory agent is a selective COX-2 inhibitor. A selective COX-2 inhibitor is a compound that selectively inhibits cyclooxygenase-2 (COX-2) activity. The terms "selective COX-2 inhibitor" and "selective cyclooxygenase-2 inhibitor" interchangeably refer to a therapeutic compound that selectively inhibits the COX-2 isoform of the enzyme cyclooxygenase,
- 15 with less significant inhibition of cyclooxygenase-1 (COX-1). As used herein the term "selective COX-2 inhibitor" also refers to a prodrug or salt that is converted *in vivo* to a compound that exhibits selective inhibition of COX-2 relative to COX-1. Preferred selective COX-2 inhibitors exhibit a selectivity factor of at least about 10, more preferably at least about 50 and still more preferably at least about 100, wherein
- 20 "selectivity factor" is defined as $IC_{50}(COX-1)/IC_{50}(COX-2)$, IC_{50} being the concentration of a compound producing 50% inhibition of enzyme activity in an *in vitro* or *in vivo* test.
- Selective COX-2 inhibitors applicable to the invention include, but are not limited to, the compounds described below and include tautomers, stereoisomers,
- 25 enantiomers, salts, hydrates, prodrugs and combinations thereof. Any such selective COX-2 inhibitory drug or prodrug known in the art can be used.
- A preferred selective COX-2 inhibitory drug useful herein is a compound of formula (I):



or a prodrug or pharmaceutically acceptable salt thereof, wherein:

A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings, preferably a heterocyclyl group selected from pyrazolyl, furanonyl, isoxazolyl, pyridinyl, cyclopentenonyl and pyridazinonyl groups;

X is O, S or CH₂;

n is 0 or 1;

R¹ is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, and is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxy, carbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;


R² is methyl, amino or aminocarbonylalkyl;

R³ is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxy, carbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxyaralkyl, aminocarbonyl, aminocarbonylalkyl, alkylaminocarbonyl, N-arylaminocarbonyl, N-alkyl-N-arylaminocarbonyl, alkylaminocarbonylalkyl, carboxyalkyl, alkylamino, N-arylmino, N-aralkylamino, N-alkyl-N-aralkylamino, N-alkyl-N-arylmino, aminoalkyl, alkylaminoalkyl, N-arylminoalkyl, N-aralkylaminoalkyl, N-alkyl-N-aralkylaminoalkyl, N-alkyl-N-arylminoalkyl, aryloxy, aralkoxy, arylthio, aralkylthio, alkylsulfinyl,

alkylsulfonyl, aminosulfonyl, alkylaminosulfonyl, N-arylamino sulfonyl, arylsulfonyl and N-alkyl-N-arylamino sulfonyl, R^3 being optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio; and


R^4 is selected from hydrido and halo.

A particularly preferred group of selective COX-2 inhibitory drugs are compounds having the formula (II):



where R^5 is a methyl or amino group, R^6 is hydrogen or a C_{1-4} alkyl or alkoxy group, X' is N or CR^7 where R^7 is hydrogen or halogen, and Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is optionally substituted at one or more positions with oxo, halo, methyl or halomethyl groups, or an isomer, tautomer, pharmaceutically-acceptable salt or prodrug thereof. Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.

Another particularly preferred group of selective COX-2 inhibitory drugs are compounds having the formula (III):



where X'' is O, S or N-lower alkyl; R^8 is lower haloalkyl; R^9 is hydrogen or halogen; R^{10} is hydrogen, halogen, lower alkyl, lower alkoxy or haloalkoxy, lower aralkylcarbonyl, lower dialkylaminosulfonyl, lower alkylaminosulfonyl, lower

aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, or 5- or 6- membered nitrogen-containing heterocyclosulfonyl; and R¹¹ and R¹² are independently hydrogen, halogen, lower alkyl, lower alkoxy, or aryl; and pharmaceutically acceptable salts thereof.

5 A particularly useful compound of formula (III) is (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid.

Another particularly preferred group of selective COX-2 inhibitory drugs are 5-alkyl-2-arylaminophenylacetic acids and derivatives thereof. Particularly useful compounds of this class are lumiracoxib and pharmaceutically acceptable salts
10 thereof.

Illustratively, celecoxib, deracoxib, valdecoxib, parecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide and their salts, more particularly celecoxib, deracoxib, valdecoxib, parecoxib and its salts, rofecoxib, etoricoxib, lumiracoxib, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide and 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide are useful in the method and composition of the invention.
20

Valdecoxib used in compositions of the invention can be prepared by any known process, for example in the manner set forth in U.S. Patent No. 5,633,272 to Talley *et al.* Parecoxib and salts thereof used in compositions of the invention can be prepared by any known process, for example in the manner set forth in U.S. Patent
25 No. 5,932,598 to Talley *et al.* Rofecoxib used in compositions of the invention can be prepared by any known process, for example in the manner set forth in U.S. Patent No. 5,474,995 to Ducharme *et al.* Etoricoxib used in compositions of the invention can be prepared by any known process, for example in the manner set forth in
30 International Patent Publication No. WO 98/03484. 2-(3,5-Difluorophenyl)-3-[4-(methylsulfonyl) phenyl]-2-cyclopenten-1-one used in compositions of the invention can be prepared by any known process, for example in the manner set forth in European Patent No. 0 863 134. Deracoxib used in compositions of the invention can

be prepared by any known process, for example in the manner set forth in U.S. Patent No. 5,466,823 to Talley *et al.* 2-(3,4-Difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone used in compositions of the invention can be prepared by any known process, for example in the manner set forth in International Patent Publication No. WO 00/24719. Other selective COX-2 inhibitory drugs can be prepared by any known process, including processes set forth in patent publications disclosing such drugs; for example in the case of celecoxib in above-cited U.S. Patent No. 5,466,823 or in U.S. Patent No. 5,892,053 to Zhi *et al.* All patents and publications cited above are incorporated herein by reference.

Where the second agent is a selective COX-2 inhibitor a preferred concentration range in a composition of the invention is about 0.01 to about 1000 mg/ml, more preferably about 0.1 to about 750 mg/ml, and still more preferably about 5 to about 250 mg/ml. For second agents other than a selective COX-2 inhibitor, suitable concentration ranges can be determined by one of skill in the art based upon published data.

Amphipathic oils applicable to the current invention include all amphipathic oils that are water dispersible and ethanol insoluble.

Preferred such amphipathic oils are polyglycolized glycerides prepared by an alcohololysis reaction of natural triglycerides with polyethylene glycols, and examples include, but are not limited to, the following Gattefossé oils or substantially equivalent oils from another manufacturer: Labrafil™ M-1944CS, Labrafil™ M-1966CS, Labrafil™ M-1969CS, Labrafil™ M-1980CS, Labrafil™ M-2125CS, Labrafil™ WL-2609BS, Labrafil™ ISO and combinations thereof.

Still more preferred amphipathic oils are polyglycolized glycerides prepared as above, comprising a main fatty acid component of either oleic acid or linoleic acid, and examples include, but are not limited to, the following Gattefossé oils or substantially equivalent oils from another manufacturer: Labrafil™ M-1944CS, Labrafil™ M-1966CS, Labrafil™ M-1969CS, Labrafil™ M-1980CS, Labrafil™ M-2125CS, Labrafil™ WL-2609BS and combinations thereof.

Still more preferred amphipathic oils are polyglycolized glycerides prepared as above, comprising a main fatty acid component of oleic acid, and examples include, but are not limited to, the following Gattefossé oils or substantially equivalent oils from another manufacturer: Labrafil™ M-1944CS, Labrafil™ M-1966CS, Labrafil™

M-1980CS and combinations thereof.

The most preferred amphipathic oil is pegicol 5-oleate, for example Labrafil™ M-1944CS of Gattfossé Corporation.

A preferred concentration range for the amphipathic oil in a composition of the invention is about 0.01% to about 99% weight/volume, more preferably about 1% to about 80% weight/volume, and still more preferably about 3% to about 25% weight/volume.

Microcrystalline wax is as defined for example in *Handbook of Pharmaceutical Excipients*, 3rd ed. or in *National Formulary*, 19th ed. (NF 19) and can be obtained from a number of manufacturers including Witco Corporation.

A preferred concentration range for microcrystalline wax in a composition of the invention is about 0.001% to about 50% weight/volume, more preferably about 0.1% to about 40% weight/volume, and still more preferably about 1% to about 15% weight/volume.

Pharmaceutically acceptable non-aqueous carriers of the invention can be fully saturated, or partially or fully unsaturated. Examples of non-aqueous carriers include, but are not limited to, vegetable oils, mineral oils, synthetic oils and combinations thereof. Examples of fully saturated non-aqueous carriers include, but are not limited to, esters of medium to long chain fatty acids (such as fatty acid triglycerides with a chain length of about C₆ to about C₂₄). Mixtures of fatty acids are split from the natural oil (for example coconut oil, palm kernel oil, babassu oil, or the like) and are refined. In some embodiments, medium chain (about C₈ to about C₁₂) triglycerides are useful. An illustrative saturated non-aqueous carrier comprises capric acid (about 20% to about 45%) and caprylic acid (about 45% to about 80%). Other fully saturated non-aqueous carriers include, but are not limited to, saturated coconut oil (which typically includes a mixture of lauric, myristic, palmitic, capric and caproic acids), including those sold under the Miglyol™ trademark from Huls and bearing trade designations 810, 812, 829 and 840). Also noted are the NeoBee™ products sold by Drew Chemicals. Isopropyl myristate is another example of a non-aqueous carrier useful in compositions of the invention. Examples of synthetic oils include triglycerides and propylene glycol diesters of saturated or unsaturated fatty acids having 6 to 24 carbon atoms such as, for example hexanoic acid, octanoic (caprylic), nonanoic (pelargonic), decanoic (capric), undecanoic, lauric, tridecanoic,

tetradecanoic (myristic), pentadecanoic, hexadecanoic (palmitic), heptadecanoic, octadecanoic (stearic), nonadecanoic, heptadecanoic, eicosanoic, heneicosanoic, docosanoic and lignoceric acids, and the like. Examples of unsaturated carboxylic acids include oleic, linoleic and linolenic acids, and the like. It is understood that the non-aqueous carrier can comprise the mono-, di- and triglyceryl esters of fatty acids or mixed glycerides and/or propylene glycol diesters wherein at least one molecule of glycerol has been esterified with fatty acids of varying carbon atom length. A non-limiting example of a "non-oil" useful as a carrier in compositions of the invention is polyethylene glycol.

Preferred non-aqueous carriers are vegetable oils such as cottonseed oil, corn oil, sesame oil, soybean oil, olive oil, fractionated coconut oil, peanut oil, sunflower oil, safflower oil, almond oil, avocado oil, palm oil, palm kernel oil, babassu oil, beechnut oil, linseed oil, rape oil and the like. The most preferred non-aqueous carrier is cottonseed oil. By way of example cottonseed oil is available in a preparation of 70% unsaturated fatty acids from Sigma Chemical Co.

A preferred concentration range for the non-aqueous carrier in a composition of the invention is about 0.5% to about 99% weight/volume, more preferably about 10% to about 95% weight/volume, and still more preferably about 40% to about 90% weight/volume.

A composition of the invention can optionally further comprise any conventional pharmaceutical excipient that does not deleteriously react with the essential ingredients of the composition. Such excipients include, but are not limited to, antioxidants, preservatives, suspending agents, stabilizers, solubilization agents, wetting agents, lubricants, emulsifiers, salts for influencing osmotic pressure, coloring agents, alcohols, isotonic agents, buffering agents and combinations thereof.

The composition comprising the antibacterial agent and optionally the second agent can be administered for treatment or prevention of mastitis by inserting the cannula nozzle of a mastitis syringe into the external orifice of the teat canal of an udder of a milk producing animal and infusing the composition into the udder.

The composition comprising the antibacterial agent and optionally the second agent can be administered for treatment or prevention of an otic disorder by inserting the nozzle of an ear syringe, otic drop dispenser, or other appropriate otic delivery device into the external auditory canal of the ear of a subject and infusing the

composition into the ear.

It will be appreciated that preferred amounts of compositions to be administered in a specific case will vary according to the specific composition being utilized, the mode of application, the particular situs and organism being treated, and other factors. Dosages for a given purpose can be determined using conventional considerations, for example, by customary comparison of the differential activities of the subject compositions and of a known agent, *e.g.*, by means of an appropriate conventional pharmaceutical protocol.

An illustrative suspension composition of the invention containing an antibacterial agent, *e.g.*, ceftiofur hydrochloride and a second agent, *e.g.*, the selective COX-2 inhibitor deracoxib, has the following composition:

	antibacterial agent	1-150 mg/ml
	second agent	1-350 mg/ml
	Labrafil™ M-1944CS	1-75%
15	microcrystalline wax	0.1-25%
	cottonseed oil	<i>q.s.</i> to 100%

(all percentages are weight/volume).

EXAMPLES

The following examples illustrate aspects of the present invention but should not be construed as limitations.

Example 1

A suspension to be administered by intramammary infusion was prepared having the following composition:

	ceftiofur hydrochloride (micronized)	12.5 mg/ml
25	Labrafil™ M-1944CS	50 mg/ml
	microcrystalline wax NF	70 mg/ml
	cottonseed oil NF	<i>q.s.</i>

The microcrystalline wax and approximately 27% of the total amount of the cottonseed oil were heated to 85-98°C with mixing, in a kettle. The balance of the cottonseed oil was heated to 85-98°C with mixing, in a manufacturing tank. After the microcrystalline wax was completely melted the microcrystalline wax/cottonseed oil mixture in the kettle was transferred to the manufacturing tank containing cottonseed

oil and mixed thoroughly. The resulting mixture was cooled to 38–45°C and the Labrafil™ M-1944CS was added to the manufacturing tank with mixing to form a vehicle. The ceftiofur hydrochloride was then added to the vehicle and the resulting composition was mixed to form a uniform suspension. The suspension was screened
 5 and filled into 12 ml high density polyethylene mastitis syringes. The packaged product was terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

The interfacial tension of the above suspension was determined using the drop volume technique with deionized water at 39°C by comparison with that of a reference suspension prepared with 70 mg/ml microcrystalline wax in cottonseed oil but without
 10 Labrafil™ M-1944CS.

The interfacial tension of the suspension containing both Labrafil™ M-1944CS and microcrystalline wax in cottonseed oil was 6.5 dyne/cm, about 3.4 times lower than that of the reference suspension (22.5 dyne/cm).

The above suspension is administered at a dose of 125 mg/quarter/day (for
 15 from 2 to 8 days) by intramammary infusion to a lactating cow, in combination therapy with a parenteral injection of 100 mg/ml parecoxib sodium in a vehicle of phosphate buffered saline administered at a dose of 4 mg/kg of body weight/day. The combination therapy is effective in treatment of lactating cow mastitis.

Example 2

20 A suspension to be administered by intramammary infusion was prepared having the following composition:

ceftiofur hydrochloride (micronized)	12.5 mg/ml
Labrafil™ M-1944CS	50 mg/ml
microcrystalline wax NF	100 mg/ml
25 cottonseed oil NF	<i>q.s.</i>

The microcrystalline wax and cottonseed oil were heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax was completely melted the mixture was cooled to 38–45°C and the Labrafil™ M-1944CS was added to the manufacturing tank with mixing to form the vehicle. Ceftiofur hydrochloride
 30 was added to the resulting vehicle and mixed to form a uniform suspension. The suspension was screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product was terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

The interfacial tension of the above suspension was determined using the drop volume technique with deionized water at 39°C by comparison with that of a reference suspension prepared with 100 mg/ml microcrystalline wax in cottonseed oil but without Labrafil™ M-1944CS.

- 5 The interfacial tension of the suspension containing both Labrafil™ M-1944CS and microcrystalline wax in cottonseed oil was 7.1 dyne/cm, about 4.0 times lower than that of the reference suspension (28.1 dyne/cm).

- The above suspension is administered by intramammary infusion at a dose of 125 mg/quarter/day (for 2 to 8 days) to a lactating cow, in combination therapy with a
10 parenteral injection of 200 mg/ml parecoxib sodium in a vehicle of phosphate buffered saline administered at a dose of 4 mg/kg of body weight/day. The combination therapy is effective in treatment of lactating cow mastitis.

Example 3

- A suspension to be administered by intramammary infusion was prepared
15 having the following composition:

ceftiofur hydrochloride (micronized)	12.5 mg/ml
Labrafil™ M-1944CS	200 mg/ml
microcrystalline wax NF	100 mg/ml
cottonseed oil NF	<i>q.s.</i>

- 20 The microcrystalline wax and cottonseed oil were heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax was completely melted the mixture was cooled to 38–45°C and Labrafil™ M-1944CS was added to the manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride was then added to the resulting vehicle and mixed to form a uniform suspension. The
25 suspension was screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product was terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

- The interfacial tension of the above suspension was determined using the drop volume technique with deionized water at 39°C by comparison with that of a reference
30 suspension prepared with 100 mg/ml microcrystalline wax in cottonseed oil but without Labrafil™ M-1944CS.

 The interfacial tension of the suspension containing both Labrafil™ M-1944CS and microcrystalline wax in cottonseed oil was <1 dyne/cm, more than 28

times lower than that of the reference suspension (28.1 dyne/cm).

The above suspension is administered at a dose of 125 mg/quarter/day (for 2 to 8 days) by intramammary infusion to a lactating cow, in combination therapy with a parenteral injection of 100 mg/ml parecoxib sodium in a vehicle of 15% polyethylene glycol in phosphate buffered saline administered at a dose of 4 mg/kg of body weight/day. The combination therapy is effective in treatment of lactating cow mastitis.

Example 4

A suspension to be administered by intramammary infusion is prepared having the following composition:

ceftiofur crystalline free acid (micronized)	25 mg/ml
deracoxib	170 mg/ml
Labrafil™ M-1966CS	100 mg/ml
microcrystalline wax NF	50 mg/ml
corn oil NF	<i>q.s.</i>

The microcrystalline wax and the corn oil are heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the mixture is cooled to 30–45°C and the Labrafil™ M-1966CS is added to the manufacturing tank with mixing to form a vehicle. The ceftiofur crystalline free acid and the deracoxib are added to the vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

The above suspension is administered to all four quarters of a dry cow at a dose of 500 mg ceftiofur crystalline free acid/quarter and 3,400 mg deracoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

Example 5

A suspension to be administered by otic infusion is prepared having the following composition:

ceftiofur hydrochloride (micronized)	25 mg/ml
rofecoxib	25 mg/ml

Labrafil™ M-1980CS	500 mg/ml
microcrystalline wax NF	0.10 mg/ml
propyl gallate	1.0 mg/ml
mineral oil	<i>q.s.</i>

- 5 The microcrystalline wax and approximately 27% of the total amount of mineral oil are heated to 85–98°C with mixing, in a kettle. The balance of the mineral oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/mineral oil mixture in the kettle is transferred to the manufacturing tank containing mineral oil and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1980CS is added to the manufacturing tank with mixing. The propyl gallate is added to the manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride and the rofecoxib are added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 20 ml polypropylene containers.

The above suspension is administered at a dose of 2.5 mg ceftiofur hydrochloride/kg body weight and 2.5 mg rofecoxib/kg of body weight, by infusion to the ear of a dog. The suspension is effective in treatment of canine otitis externa.

Example 6

- 20 A suspension to be administered by intramammary infusion is prepared having the following composition:

ceftiofur hydrochloride (micronized)	50 mg/ml
deracoxib	300 mg/ml
Labrafil™ M-1944CS	50 mg/ml
25 microcrystalline wax NF	70 mg/ml
cottonseed oil NF	<i>q.s.</i>

- The microcrystalline wax and approximately 27% of the total amount of the cottonseed oil are heated to 85–98°C with mixing, in a kettle. The balance of the cottonseed oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/cottonseed oil mixture in the kettle is transferred to the manufacturing tank containing cottonseed oil and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the manufacturing tank with mixing to form the vehicle. The

ceftiofur hydrochloride and deracoxib are added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

- 5 The above suspension is administered to all four quarters of a dry cow at a dose of 500 mg ceftiofur hydrochloride/quarter and 12,000 mg deracoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

Example 7

- 10 A suspension to be administered by intramammary infusion is prepared having the following composition:

ceftiofur sodium (micronized)	25 mg/ml
valdecoxib	1.5 mg/ml
Labrafil™ WL-2609BS	75 mg/ml
microcrystalline wax NF	100 mg/ml
15 Miglyol™ 812	<i>q.s.</i>

- The microcrystalline wax and approximately 30% of the total amount of the Miglyol™ 812 are heated to 85–98°C with mixing, in a kettle. The balance of the Miglyol™ 812 is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/Miglyol™ 812 mixture in the kettle is transferred to the manufacturing tank containing the Miglyol™ 812 and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ WL-2609BS is added to the manufacturing tank with mixing to form the vehicle. The ceftiofur sodium and the valdecoxib are added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 25 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

The above suspension is administered to all four quarters of a dry cow at a dose of 500 mg ceftiofur sodium/quarter and 30 mg valdecoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

Example 8

30 A suspension to be administered by otic infusion is prepared having the following composition:

ceftiofur hydrochloride (micronized)	100 mg/ml
deracoxib	100 mg/ml
Labrafil™ M-1944CS	700 mg/ml
microcrystalline wax NF	0.05 mg/ml
mineral oil	<i>q.s.</i>

The microcrystalline wax and approximately 27% of the total amount of mineral oil are heated to 85–98°C with mixing, in a kettle. The balance of the mineral oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/mineral oil mixture in the kettle is transferred to the manufacturing tank containing mineral oil and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride and the deracoxib are added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 50 ml polypropylene containers.

The above suspension is administered at a dose of 4 mg ceftiofur hydrochloride/kg body weight and 4 mg deracoxib/kg of body weight by infusion to the ear of a subject. The suspension is effective in treatment and/or prevention of otitis media.

20 Example 9

A suspension to be administered by otic infusion is prepared having the following composition:

ceftiofur hydrochloride (micronized)	100 mg/ml
Labrafil™ M-1944CS	700 mg/ml
microcrystalline wax NF	0.1 mg/ml
cottonseed oil NF	<i>q.s.</i>

The microcrystalline wax and cottonseed oil are heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride is added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 60 ml polypropylene containers.

The above suspension is administered at a dose of 4 mg ceftiofur

hydrochloride/kg body weight by infusion into the ear of a subject, in combination therapy with oral administration of a 200 mg Celebrex® (celecoxib) capsule given twice per day. The combination therapy is effective in treatment and/or prevention of otitis externa.

5 Example 10

A suspension to be administered by otic infusion is prepared having the following composition:

	ceftiofur hydrochloride (micronized)	75 mg/ml
	Labrafil™ M-1944CS	750 mg/ml
10	microcrystalline wax NF	0.05 mg/ml
	mineral oil	<i>q.s.</i>

The microcrystalline wax and mineral oil are heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the
15 manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride is added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into a 20 ml polypropylene delivery device.

The above suspension is administered at a dose of 2 mg ceftiofur hydrochloride/kg body weight by infusion into the ear of a subject, in combination
20 therapy with oral administration of a 10 mg Bextra® (valdecoxib) tablet given once a day. The combination therapy is effective in treatment of infectious myringitis.

Example 11

A suspension to be administered by otic infusion is prepared having the following composition:

25	ceftiofur hydrochloride (micronized)	100 mg/ml
	parecoxib free acid	100 mg/ml
	Labrafil™ M-1944CS	700 mg/ml
	microcrystalline wax NF	0.1 mg/ml
	cottonseed oil NF	<i>q.s.</i>

30 The microcrystalline wax and cottonseed oil are heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the

manufacturing tank with mixing to form the vehicle. The ceftiofur hydrochloride and parecoxib are added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 60 ml polypropylene containers.

- The above suspension is administered at a dose of 4 mg ceftiofur
 5 hydrochloride/kg body weight and 4 mg parecoxib/kg of body weight by infusion into the ear of a subject. The combination therapy is effective in treatment and/or prevention of otitis externa.

Example 12

- A suspension to be administered by intramammary infusion is prepared having
 10 the following composition:

parecoxib free acid	100 mg/ml
Labrafil™ M-1944CS	50 mg/ml
microcrystalline wax NF	70 mg/ml
cottonseed oil NF	<i>q.s.</i>

- 15 The microcrystalline wax and approximately 27% of the total amount of the cottonseed oil are heated to 85–98°C with mixing, in a kettle. The balance of the cottonseed oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted the microcrystalline wax/cottonseed oil mixture in the kettle is transferred to the manufacturing tank containing cottonseed oil
 20 and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the manufacturing tank with mixing to form a vehicle. The parecoxib is then added to the vehicle and the resulting composition is mixed to form a uniform suspension. The suspension is screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by
 25 gamma irradiation at a dose of 25–40 kGy.

The above suspension is administered by intramammary infusion to each infected quarter of an udder of a lactating cow at a dose of 1,200 mg parecoxib/quarter/day. The suspension is effective in treatment of lactating cow mastitis.

Example 13

A suspension to be administered by intramammary infusion is prepared having the following composition:

deracoxib	170 mg/ml
Labrafil™ M-1966CS	100 mg/ml
microcrystalline wax NF	50 mg/ml
corn oil NF	<i>q.s.</i>

- 5 The microcrystalline wax and the corn oil are heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the mixture is cooled to 30–45°C and the Labrafil™ M-1966CS is added to the manufacturing tank with mixing to form a vehicle. The deracoxib is added to the vehicle and mixed to form a uniform suspension. The suspension is screened and
- 10 filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

The above suspension is administered to all four quarters of a dry cow at a dose of 3,400 mg deracoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

15 Example 14

A suspension to be administered by otic infusion is prepared having the following composition:

rofecoxib	25 mg/ml
Labrafil™ M-1980CS	500 mg/ml
20 microcrystalline wax NF	0.10 mg/ml
propyl gallate	1.0 mg/ml
mineral oil	<i>q.s.</i>

- The microcrystalline wax and approximately 27% of the total amount of mineral oil are heated to 85–98°C with mixing, in a kettle. The balance of the mineral
- 25 oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/mineral oil mixture in the kettle is transferred to the manufacturing tank containing mineral oil and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1980CS is added to the manufacturing tank with mixing. The propyl gallate is
- 30 added to the manufacturing tank with mixing to form the vehicle. The rofecoxib is added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 20 ml polypropylene containers.

The above suspension is administered at a dose of 2.5 mg rofecoxib/kg of

body weight, by infusion to the ear of a dog. The suspension is effective in treatment of canine otitis externa.

Example 15

A suspension to be administered by intramammary infusion is prepared having
5 the following composition:

deracoxib	300 mg/ml
Labrafil™ M-1944CS	50 mg/ml
microcrystalline wax NF	70 mg/ml
cottonseed oil NF	<i>q.s.</i>

10 The microcrystalline wax and approximately 27% of the total amount of the cottonseed oil are heated to 85–98°C with mixing, in a kettle. The balance of the cottonseed oil is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/cottonseed oil
15 mixture in the kettle is transferred to the manufacturing tank containing cottonseed oil and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the Labrafil™ M-1944CS is added to the manufacturing tank with mixing to form the vehicle. The deracoxib is added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose
20 of 25–40 kGy.

The above suspension is administered to all four quarters of a dry cow at a dose of 12,000 mg deracoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

Example 16

25 A suspension to be administered by intramammary infusion is prepared having the following composition:

valdecxib	1.5 mg/ml
Labrafil™ WL-2609BS	75 mg/ml
microcrystalline wax NF	100 mg/ml
30 Miglyol™ 812	<i>q.s.</i>

The microcrystalline wax and approximately 30% of the total amount of the Miglyol™ 812 are heated to 85–98°C with mixing, in a kettle. The balance of the

Miglyol™ 812 is heated to 85–98°C with mixing, in a manufacturing tank. After the microcrystalline wax is completely melted, the microcrystalline wax/Miglyol™ 812 mixture in the kettle is transferred to the manufacturing tank containing the Miglyol™ 812 and mixed thoroughly. The resulting mixture is cooled to 38–45°C and the

5 Labrafil™ WL-2609BS is added to the manufacturing tank with mixing to form the vehicle. The valdecoxib is added to the resulting vehicle and mixed to form a uniform suspension. The suspension is screened and filled into 12 ml high density polyethylene mastitis syringes. The packaged product is terminally sterilized by gamma irradiation at a dose of 25–40 kGy.

10 The above suspension is administered to all four quarters of a dry cow at a dose of 30 mg valdecoxib/quarter by intramammary infusion. The suspension is effective in treatment of dry cow mastitis.

15

The invention having been described in detail and by reference to the preferred embodiments thereof, it will be apparent that modifications and variations are possible without departing from the scope of the appended claims. Said modifications and variations include using in place of ceftiofur other antibiotics such as cephalalexin,

20 cephradine, cefquinome, cephacetrile, cefpodoxime, cefovecin, cephalonium, cefuroxime, cefazidime, cefoperazone, sodium cephemethcarboxylate, cephem, cephadroxil, cephalolin sodium, cefiximine, ceftaxime, ceftizoxime, ceftriaxone and pharmaceutically acceptable salts thereof.

CLAIMS:

1. A method of treatment and/or prevention of an infective condition in a fluid-containing organ having a natural exterior orifice, the method comprising administering an antibacterial agent to the organ via the exterior orifice and
5 administering in combination therapy with said antibacterial agent a second agent selected from the group consisting of anti-inflammatory agents, analgesics and antipyretics, wherein said antibacterial agent is administered as a pharmaceutical composition comprising said antibacterial agent and a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol
10 insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier.
2. The method of Claim 1 wherein the infective condition is a disease of an udder of a milk producing animal, and wherein the composition comprising the antibacterial agent is administered by intramammary infusion.
- 15 3. The method of Claim 1 wherein the infective condition is a disorder of an ear of a subject or a complication associated with such a disorder, and wherein the composition comprising the antibacterial agent is administered by otic infusion.
4. The method of Claim 1 wherein the second agent is administered as a pharmaceutical composition comprising said second agent and a vehicle that
20 comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier.
5. The method of Claim 1 wherein the antibacterial agent is selected from the group consisting of natural and synthetic penicillin-type antibiotics,
25 cephalosporins, macrolides, lincosamides, pleuromutilins, polypeptides, polymyxins, sulfonamides, chloramphenicol, thiamphenicol, florfenicol, tetracycline-type antibiotics, quinolones, fluoroquinolones, tiamulin, ciprofloxacin, colistin, domecloxycine, mafenide, methacycline, norfloxacin, ofloxacin, pyrimethamine, silver sulfadiazine, sulfacetamide, sulfoxazole,
30 tobramycin, vancomycin, oxazolidinones, glycopeptides, aminoglycosides and aminocyclitols, amphenicol, ansamycin, carbapenem, cephamycin,

vancomycin, monobactam, oxacephem, systemic antibacterials, antibiotic-type antineoplastic agents, nitrofuransulfones, marbofloxacin, and tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs thereof.

6. The method of Claim 5 wherein the cephalosporin is selected from the group consisting of ceftiofur, cephalixin, cephradine, cefquinome, cephacetrile, cefpodoxime, cefovecin, cephalonium, cefuroxime, cefazidime, cefoperazone, sodium cephemethcarboxylate, cephem, cephadroxil, cephalolin sodium, cefiximine, ceftaxime, ceftizoxime, ceftriaxone, o-formylcefamandole, salts of 3-acetoxymethyl-7-(iminocetamido)-cephalosporanic acid derivatives, 7-(D- α -amino- α -(p-hydroxyphenyl)acetamino)-3-methyl-3-cephem-1-carboxylic acid, hydrochloride salt of syn-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-3-cephem-4-carboxylic acid, cephem acid, (pivaloyloxy)methyl-7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylate, cephalixin, 7-(D-2-naphthylglycylamino)-3-methyl-3-cephem-4-carboxylic acid, and tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs thereof.
7. The method of Claim 1 wherein the antibacterial agent is ceftiofur or a pharmaceutically acceptable salt thereof.
8. The method of Claim 1 wherein the second agent is selected from the group consisting of aceclofenac, acetaminophen, acetaminosalol, acetanilide, acetylsalicylic acid, S-adenosylmethionine, alclofenac, alclometasone, alfentanil, algestone, allylprodine, alminoprofen, aloxiprin, alphaprodine, aluminum bis(acetylsalicylate), amcinonide, amfenac, aminochlorlorthenoxazin, 3-amino-4-hydroxybutyric acid, 2-amino-4-picoline, aminopropylol, aminopyrine, amixetrine, ammonium salicylate, ampiroxicam, amtolmetin guacil, anileridine, antipyrine, antrafenine, apazone, beclomethasone, bendazac, benorylate, benoxaprofen, benzpiperylon, benzydamine, benzylmorphine, bermoprofen, betamethasone, betamethasone-17-valerate, bezitramide, α -bisabolol, bromfenac, p-bromoacetanilide, 5-bromosalicylic acid acetate, bromosaligenin, buccetin, bucloxic acid, bucolome, budesonide, bufexamac, bumadizon, buprenorphine, butacetin, butibufen, butorphanol, carbamazepine, carbiphen, carprofen, carsalam,

celecoxib, chlorobutanol, chloroprednisone, chlorthenoxazin, choline salicylate,
 cinchophen, cinmetacin, cirmadol, clidanac, clobetasol, clocortolone,
 clometacin, clonitazene, clonixin, clopirac, cloprednol, clove, codeine, codeine
 methyl bromide, codeine phosphate, codeine sulfate, cortisone, cortivazol,
 5 cropropamide, crotethamide, cyclazocine, deflazacort, dehydrotestosterone,
 deracoxib, desomorphine, desonide, desoximetasone, dexamethasone,
 dexamethasone-21-isonicotinate, dexoadrol, dextromoramide,
 dextropropoxyphene, deoxycorticosterone, dezocine, diampromide,
 diamorphine, diclofenac, difenamizole, difenpiramide, diflorasone,
 10 diflucortolone, diflunisal, difluprednate, dihydrocodeine, dihydrocodeinone enol
 acetate, dihydromorphine, dihydroxyaluminum acetylsalicylate, dimenoxadol,
 dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone,
 diprocetyl, dipyrone, ditazol, droxicam, emorfazone, enfenamic acid, enoxolone,
 eptazocine, epirizole, etersalate, ethenzamide, ethoheptazine, ethoxazene,
 15 ethylmethylthiambutene, ethylmorphine, etodolac, etofenamate, etonitazene,
 etoricoxib, eugenol, felbinac, fenbufen, fenclozic acid, fendosal, fenoprofen,
 fentanyl, fentiazac, fepradinol, feprazone, floctafenine, fluazacort, flucoronide,
 flufenamic acid, flumethasone, flunisolid, flunixin, flunoxaprofen, fluocinolone
 acetonide, fluocinonide, fluocinolone acetonide, fluocortin butyl, fluocortolone,
 20 fluoresone, fluorometholone, fluperolone, flupirtine, flurandrenolone acetonide,
 fluorometholone, fluprednidene, fluprednisolone, fluproquazone,
 flurandrenolide, flurandrenolide, flurandrenolone acetonide, flurbiprofen,
 fluticasone, formocortol, fosfosal, gentisic acid, glafenine, glucametacin, glycol
 salicylate, guaiazulene, halcinonide, halobetasol, halometasone, haloprednone,
 25 heroin, hydrocodone, hydrocortamate, hydrocortisone, hydrocortisone acetate,
 hydrocortisone succinate, hydrocortisone hemisuccinate, hydrocortisone 21-
 lysinate, hydrocortisone cypionate, hydromorphone, hydroxypethidine, ibufenac,
 ibuprofen, ibuproxam, imidazole salicylate, indomethacin, indoprofen,
 isofezolac, isoflupredone, isoflupredone acetate, isoladol, isomethadone,
 30 isonixin, isoxepac, isoxicam, ketobemidone, ketoprofen, ketorolac,
p-lactophenetide, lefetamine, levallorphan, levorphanol, levophenacyl-morphan,
 lofentanil, lonazolac, lornoxicam, loxoprofen, lumiracoxib, lysine
 acetylsalicylate, mazipredone, meclofenamic acid, medrysone, mefenamic acid,

- meloxicam, meperidine, meprednisone, meptazinol, mesalamine, metazocine, methadone, methotrimeprazine, methylprednisolone, methylprednisolone acetate, methylprednisolone sodium succinate, methylprednisolone suleptnate, metiazinic acid, metofoline, metopon, mofebutazone, mofezolac, mometasone, morazone, morphine, morphine hydrochloride, morphine sulfate, morpholine salicylate, myrophine, nabumetone, nalbuphine, nalophine, 1-naphthyl salicylate, naproxen, narceine, nefopam, nicomorphine, nifenazone, niflumic acid, nimesulide, 5'-nitro-2'-propoxyacetanilide, norlevorphanol, normethadone, normorphine, norpipanone, olsalazine, opium, oxaceprol, oxametacine, oxaprozin, oxycodone, oxymorphone, oxyphenbutazone, papaveretum, paramethasone, paranyline, parecoxib, parsalmide, pentazocine, perisoxal, phenacetin, phenadoxone, phenazocine, phenazopyridine hydrochloride, phenocoll, phenoperidine, phenopyrazone, phenomorphan, phenyl acetylsalicylate, phenylbutazone, phenyl salicylate, phenylramidol, piketoprofen, piminodine, pipebuzone, piperylone, piprofen, pirazolac, piritramide, piroxicam, pranoprofen, prednicarbate, prednisolone, prednisone, prednival, prednylidene, proglumetacin, proheptazine, promedol, propacetamol, properidine, proheptazine, propiram, propoxyphene, propyphenazone, proquazone, protizinic acid, proxazole, ramifenazone, remifentanil, rimazolium metilsulfate, rofecoxib, salacetamide, salicin, salicylamide, salicylamide *o*-acetic acid, salicylic acid, salicylsulfuric acid, salsalate, salverine, simetride, sufentanil, sulfasalazine, sulindac, superoxide dismutase, suprofen, suxibuzone, talniflumate, tenidap, tenoxicam, terofenamate, tetrandrine, thiazolinobutazone, tiaprofenic acid, tiaramide, tilidine, tinoridine, tixocortol, tolfenamic acid, tolmetin, tramadol, triamcinolone, triamcinolone acetoneide, tropesin, valdecocib, viminol, xenbucin, ximoprofen, zaltoprofen and zomepirac.
9. The method of Claim 1 wherein the second agent is a non-steroidal anti-inflammatory drug.
 10. The method of Claim 9 wherein the non-steroidal anti-inflammatory drug is selected from the group consisting of deracoxib, parecoxib, celecoxib, valdecocib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-

(trifluoromethyl)-2H-1-benzopyran-3-carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, salts and prodrugs thereof.

11. A pharmaceutical composition comprising a vehicle that comprises (a) an amphipathic oil that is water dispersible and ethanol insoluble, (b) microcrystalline wax and (c) a pharmaceutically acceptable non-aqueous carrier; said vehicle having stably dispersed therein an antibacterial agent in an antibacterially effective amount and a second agent selected from the group consisting of anti-inflammatory agents, analgesics and antipyretics in a therapeutically effective amount.
12. The composition of Claim 11 wherein the amphipathic oil is a polyglycolized glyceride prepared by an alcohololysis reaction of natural triglycerides with polyethylene glycols.
13. The composition of Claim 11 wherein the antibacterial agent is selected from the group consisting of ceftiofur, cephalexin, cephadrine, cefquinome, cephacetrile, cefpodoxime, cefovecin, cephalonium, cefuroxime, cefazidime, cefoperazone, sodium cephemethcarboxylate, cephem, cephadroxil, cephazolin sodium, cefiximine, ceftaxime, ceftizoxime, ceftriaxone, o-formylcefamandole, salts of 3-acetoxymethyl-7-(iminocetamido)-cephalosporanic acid derivatives, 7-(D- α -amino- α -(p-hydroxyphenyl)acetamino)-3-methyl-3-cephem-1-carboxylic acid, hydrochloride salt of syn-7-((2-amino-1-thiazolyl)(methoxyimino)acetyl)amino)-3-methyl-3-cephem-4-carboxylic acid, cephem acid, (pivaloyloxy)methyl-7-beta-(2-(2-amino-4-thiazolyl)acetamido)-3-(((1-(2-(dimethylamino)ethyl)-1H-tetrazol-5-yl)thio)methyl)-3-cephem-4-carboxylate, cephalexin, 7-(D-2-naphthylglycylamino)-3-methyl-3-cephem-4-carboxylic acid, and tautomers, stereoisomers, enantiomers, salts, hydrates and prodrugs thereof.
14. The composition of Claim 12 wherein the second agent is selected from the group consisting of deracoxib, parecoxib, celecoxib, valdecoxib, rofecoxib, etoricoxib, lumiracoxib, 2-(3,5-difluorophenyl)-3-[4-(methylsulfonyl)phenyl]-2-cyclopenten-1-one, (S)-6,8-dichloro-2-(trifluoromethyl)-2H-1-benzopyran-3-

carboxylic acid, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3-methyl-1-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, 4-[5-(4-fluorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, 4-[5-(phenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide, salts and prodrugs thereof.

5

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K47/44 A61K45/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	OWENS W E ET AL: "DETERMINATION OF MILK AND MAMMARY TISSUE CONCENTRATIONS OF CEFTIOFUR AFTER INTRAMAMMARY AND INTRAMUSCULAR THERAPY" JOURNAL OF DAIRY SCIENCE, vol. 73, no. 12, 1990, pages 3449-3456, XP002291861 ISSN: 0022-0302 abstract page 3450, left-hand column, paragraph 3	1-14
A	WO 98/25621 A (FOSTER TODD P ; UPJOHN CO (US); KIEFER DAVID L (US)) 18 June 1998 (1998-06-18) page 6, line 19 - line 32 examples 1,2 ----- -/-	1-14

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"Z" document member of the same patent family

Date of the actual completion of the international search

13 August 2004

Date of mailing of the international search report

26/08/2004

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Epskamp, S

INTERNATIONAL SEARCH REPORT

Publication No.
P/IB2004/000802

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96/39146 A (BAYER AG) 12 December 1996 (1996-12-12) page 1, line 6 - line 9; examples -----	1-14
A	US 2001/049366 A1 (SINGH ONKAR N ET AL) 6 December 2001 (2001-12-06) examples -----	1-14
A	GB 1 370 699 A (DYNAMIT NOBEL AG) 16 October 1974 (1974-10-16) page 2, line 27 - line 33 example 4 -----	1-14

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: —
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1-10 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9825621	A	18-06-1998	US 5736151 A AT 264681 T AU 746666 B2 AU 5452998 A BR 9714967 A CA 2269682 A1 CN 1238690 A CZ 9902025 A3 DE 69728783 D1 DK 941095 T3 EP 0941095 A1 FI 991302 A HU 0000564 A2 JP 2001505910 T NO 992780 A NZ 336183 A SK 72399 A3 WO 9825621 A1	07-04-1998 15-05-2004 02-05-2002 03-07-1998 30-10-2001 18-06-1998 15-12-1999 15-09-1999 27-05-2004 02-08-2004 15-09-1999 08-06-1999 28-10-2000 08-05-2001 08-06-1999 22-12-2000 16-05-2000 18-06-1998
WO 9639146	A	12-12-1996	AT 214931 T AU 708540 B2 AU 5984096 A CA 2199294 A1 CN 1160999 A , C DE 69620136 D1 DE 69620136 T2 DK 782448 T3 EP 0782448 A1 ES 2173287 T3 IL 120317 A NZ 309624 A PT 782448 T TW 464499 B WO 9639146 A1 US 5965549 A US 5843930 A ZA 9604653 A	15-04-2002 05-08-1999 24-12-1996 12-12-1996 01-10-1997 02-05-2002 01-08-2002 08-07-2002 09-07-1997 16-10-2002 13-08-2000 29-04-1999 31-07-2002 21-11-2001 12-12-1996 12-10-1999 01-12-1998 12-12-1996
US 2001049366	A1	06-12-2001	NONE	
GB 1370699	A	16-10-1974	DE 2063896 A1 FR 2121039 A5 NL 7113689 A	20-07-1972 18-08-1972 30-06-1972